WO2024084082A1 - Adipocyte maturation - Google Patents
Adipocyte maturation Download PDFInfo
- Publication number
- WO2024084082A1 WO2024084082A1 PCT/EP2023/079366 EP2023079366W WO2024084082A1 WO 2024084082 A1 WO2024084082 A1 WO 2024084082A1 EP 2023079366 W EP2023079366 W EP 2023079366W WO 2024084082 A1 WO2024084082 A1 WO 2024084082A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pluripotent stem
- protein
- stem cell
- days
- cebpa
- Prior art date
Links
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 67
- 230000035800 maturation Effects 0.000 title description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 79
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 59
- 210000004027 cell Anatomy 0.000 claims description 100
- 230000004069 differentiation Effects 0.000 claims description 83
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 229940125396 insulin Drugs 0.000 claims description 42
- 102000004877 Insulin Human genes 0.000 claims description 41
- 108090001061 Insulin Proteins 0.000 claims description 41
- 230000001939 inductive effect Effects 0.000 claims description 41
- 230000002103 transcriptional effect Effects 0.000 claims description 40
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 39
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 39
- 230000002068 genetic effect Effects 0.000 claims description 32
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 28
- 229960003957 dexamethasone Drugs 0.000 claims description 25
- 235000013372 meat Nutrition 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 20
- 239000004098 Tetracycline Substances 0.000 claims description 18
- 229960002180 tetracycline Drugs 0.000 claims description 18
- 229930101283 tetracycline Natural products 0.000 claims description 18
- 235000019364 tetracycline Nutrition 0.000 claims description 18
- 150000003522 tetracyclines Chemical class 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000035755 proliferation Effects 0.000 claims description 17
- 108091026890 Coding region Proteins 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims description 11
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 11
- 101710195626 Transcriptional activator protein Proteins 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 244000144972 livestock Species 0.000 claims description 8
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 101150017501 CCR5 gene Proteins 0.000 claims description 5
- 101150055030 Clybl gene Proteins 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 108010031480 Artificial Receptors Proteins 0.000 claims description 4
- 101150061453 Cebpa gene Proteins 0.000 claims description 4
- 230000004568 DNA-binding Effects 0.000 claims description 4
- 102100039556 Galectin-4 Human genes 0.000 claims description 4
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 4
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 claims description 4
- 108010057466 NF-kappa B Proteins 0.000 claims description 4
- 102000003945 NF-kappa B Human genes 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000002308 embryonic cell Anatomy 0.000 claims description 4
- 108020001756 ligand binding domains Proteins 0.000 claims description 4
- 210000000636 white adipocyte Anatomy 0.000 claims description 4
- 108010016731 PPAR gamma Proteins 0.000 abstract description 2
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 33
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 33
- 150000002632 lipids Chemical class 0.000 description 19
- 108020004705 Codon Proteins 0.000 description 15
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 230000035897 transcription Effects 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 230000011759 adipose tissue development Effects 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 10
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 229960003722 doxycycline Drugs 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010076365 Adiponectin Proteins 0.000 description 7
- 102100031786 Adiponectin Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000000339 bright-field microscopy Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 108091005461 Nucleic proteins Proteins 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000006372 lipid accumulation Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 5
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 5
- 102100025169 Max-binding protein MNT Human genes 0.000 description 5
- 101150023417 PPARG gene Proteins 0.000 description 5
- 102000017795 Perilipin-1 Human genes 0.000 description 5
- 108010067162 Perilipin-1 Proteins 0.000 description 5
- 108091027981 Response element Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 108010023082 activin A Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 108091006107 transcriptional repressors Proteins 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000049320 CD36 Human genes 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000283153 Cetacea Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102100022119 Lipoprotein lipase Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 3
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 238000012604 3D cell culture Methods 0.000 description 2
- 241001455214 Acinonyx jubatus Species 0.000 description 2
- 241000282452 Ailuropoda melanoleuca Species 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 241001481833 Coryphaena hippurus Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000283070 Equus zebra Species 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101001129132 Homo sapiens Perilipin-1 Proteins 0.000 description 2
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000025174 PANDAS Diseases 0.000 description 2
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 2
- 240000004718 Panda Species 0.000 description 2
- 235000016496 Panda oleosa Nutrition 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102100031261 Perilipin-1 Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000283080 Proboscidea <mammal> Species 0.000 description 2
- 241000282330 Procyon lotor Species 0.000 description 2
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 2
- 102000051792 Promyelocytic Leukemia Zinc Finger Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- 238000012573 2D experiment Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 101000917553 Bos taurus Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000214054 Equine rhinitis A virus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 101000749825 Homo sapiens Connector enhancer of kinase suppressor of ras 1 Proteins 0.000 description 1
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 102100021001 Kinase suppressor of Ras 1 Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001672814 Porcine teschovirus 1 Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 241001648840 Thosea asigna virus Species 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000015143 herbs and spices Nutrition 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000005339 levitation Methods 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001763 pro-adipogenic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 101150076297 ywhaz gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Definitions
- the present invention relates to modified pluripotent cells and to methods of differentiating said cell into adipocytes.
- the invention relates to a pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR-y protein, wherein the coding sequence for the PPAR-y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter; wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
- the expression constructs of ii) and iii) are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site.
- said first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene, preferably wherein the genetic safe harbour site are hROSA26 locus and the AAVS1 locus.
- the cell is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, embryonic cell lines, and somatic cell lines.
- the pluripotent stem cells are of a livestock or poultry species.
- the livestock species is porcine or bovine, preferably porcine.
- the pluripotent stem cells may be of the family Suidae, for example the genus Sus, such as the species S. domesticus.
- the expression construct that is inserted into the second genetic safe harbour site encodes a PPAR-y protein a linker and a CEBPa protein, preferably wherein the linker is P2A, more preferably wherein the linker comprises the sequence of SEQ ID NO: 3.
- the construct comprises the sequence of SEQ ID NO: 4.
- the activity of the transcriptional regulator protein is controlled by an exogenously supplied substance derivative.
- the transcriptional regulator protein is selected from the group consisting of: tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor and an activation domain from the human NF-kB, preferably the transcriptional regulator protein is rtTA.
- the inducible promoter includes a Tet Responsive Element (TRE).
- TRE Tet Responsive Element
- the inducible promotor is a tetON promotor.
- the invention provides for a method for the production of adipocytes, preferably white adipocytes, comprising a ) culturing the pluripotent stem cell according to any one of the preceding claims in a proliferation medium: followed by b) inducing adipocyte differentiation by adding the exogenous substance as described herein.
- the proliferation and/or differentiation medium does not comprise or does not substantially comprise at least one compound selected from the group of insulin, dexamethasone, rosiglitazone and isobutylmethylxanthine. In certain preferred embodiments, the proliferation and/or differentiation medium does not comprise or does not substantially comprise insulin.
- a proliferation and/or differentiation medium which does not comprise or does not substantially comprise insulin may optionally comprise IGF-1 and/or LR3.
- the differentiation phase of the method as described herein is at most 10 days, at most 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days or 2 days .
- the produced adipocytes are for human and non-human dietary consumption.
- the invention provides for a use of a pluripotent stem cell as described herein or use of the method for producing a adipocyte as described herein for tissue engineering, optionally for the production of cultured meat.
- the invention provides for a food product comprising the pluripotent stem cell as described herein or the adipocytes obtained by the method as described herein.
- the food product is cultured meat.
- the term "and/or” indicates that one or more of the stated cases may occur, alone or in combination with at least one of the stated cases, up to with all of the stated cases.
- At least a particular value means that particular value or more.
- at least 2 is understood to be the same as "2 or more” i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, ... ,etc.
- the word “about” or “approximately” when used in association with a numerical value preferably means that the value may be the given value (of 10) more or less 0.1 % of the value.
- heterologous when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
- Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins that are not normally produced by the cell in which the DNA is transcribed or expressed.
- heterologous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous nucleic acid or protein.
- heterologous also applies to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
- expression vector or “expression construct” refer to nucleotide sequences that are capable of effecting expression of a gene in host cells or host organisms compatible with such sequences. These expression vectors typically include at least suitable transcription regulatory sequences and optionally, 3' transcription termination signals. Additional factors necessary or helpful in effecting expression may also be present, such as expression enhancer elements
- operably linked refers to a linkage of polynucleotide elements in a functional relationship.
- a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- a transcription regulatory sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence.
- Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein encoding regions, contiguous and in reading frame, inducible promoter
- promoter refers to a nucleic acid fragment that functions to control the transcription of one or more coding sequences, and is located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
- a “constitutive” promoter is a promoter that is active in most tissues under most physiological and developmental conditions.
- An “inducible” promoter is a promoter that is physiologically or developmentally regulated, e.g. by the application of a chemical inducer. In the case of the present invention, the control is effected by the transcriptional regulator protein.
- the inventors have surprisingly found that the time period required for differentiation of pluripotent cells into mature adipocytes can dramatically be reduced by using a modified pluripotent stem cells that comprise an expression construct for expression of a PPAR-y protein and an expression construct for expression of a CEBPa protein. As shown in the examples described herein, by using these modified pluripotent cell lines, full differentiation into mature adipocytes can be achieved in less than 10 days. Apart from significantly reducing the culturing time and the associated cost involved, the use of the herein describe pluripotent cells also provides for a more reliable and scalable production of mature adipocyte as compared to what has been previously described.
- the invention relates to a pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR-y protein, wherein the coding sequence for the PPAR-y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter; wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
- Peroxisome proliferator- activated receptor gamma is a type II nuclear receptor functioning as a transcription factor that in humans is encoded by the PPARG gene.
- PPARG is mainly present in adipose tissue, colon and macrophages. Two isoforms of PPARG are detected in the human and in the mouse: PPAR-y1 (found in nearly all tissues except muscle) and PPAR-y2 (mostly found in adipose tissue and the intestine).
- the coding sequence of PPAR-y of the invention encodes PPAR-y2.
- PPARG regulates fatty acid storage and glucose metabolism.
- the genes activated by PPARG stimulate lipid uptake and adipogenesis by fat cells.
- PPARG knockout mice are devoid of adipose tissue, establishing PPARG as a master regulator of adipocyte differentiation.
- the coding sequence for the PPAR-y has the sequence of SEQ ID NO: 1 .
- CCAAT/enhancer-binding protein alpha is a protein encoded by the CEBPA gene in humans.
- the protein encoded by this intronless gene is a bZIP transcription factor which can bind as a homodimer to certain promoters and gene enhancers. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma, as well as distinct transcription factors such as c-Jun.
- the encoded protein is a key regulator of adipogenesis (the process of forming new fat cells) and the accumulation of lipids in those cells, as well as in the metabolism of glucose and lipids in the liver.
- the coding sequence for the CEBPa has the sequence of SEQ ID NO: 2.
- the nucleic acid molecules encoding the proteins according to the invention are codon-optimized for expression in mammalian cells. Methods of codon-optimization are known and have been described previously (e.g. WO 96/09378 for mammalian cells). A sequence is considered codon-optimized if at least one non-preferred codon as compared to a wildtype sequence is replaced by a codon that is more preferred.
- a non-preferred codon is a codon that is used less frequently in an organism than another codon coding for the same amino acid, and a codon that is more preferred is a codon that is used more frequently in an organism than a non-preferred codon.
- the frequency of codon usage for a specific organism can be found in codon frequency tables, such as in http://www.kazusa.or.jp/codon.
- a transcriptional regulator protein is a protein that bind to DNA, preferably sequence- specifically to a DNA site located in or near a promoter, and either facilitating the binding of the transcription machinery to the promoter, and thus transcription of the DNA sequence (a transcriptional activator) or blocks this process (a transcriptional repressor). Such entities are also known as transcription factors.
- the DNA sequence that a transcriptional regulator protein binds to is called a transcription factor-binding site or response element, and these are found in or nearthe promoter of the regulated DNA sequence.
- Transcriptional activator proteins bind to a response element and promote gene expression. Such proteins are preferred in the methods of the present invention for controlling inducible cassette expression.
- a genetic safe harbour (GSH) site is a locus within the genome wherein a gene or other genetic material may be inserted without any deleterious effects on the cell or on the inserted genetic material. Most beneficial is a GSH site in which expression of the inserted gene sequence is not perturbed by any read-through expression from neighboring genes and expression of the inducible cassette minimizes interference with the endogenous transcription program. More formal criteria have been proposed that assist in the determination of whether a particular locus is a GSH site in future (Papapetrou et al, 2011 , Nature Biotechnology, 29(1), 73-8. doi: 1 0. 1 038/nbt.
- These criteria include a site that is (i) 50 kb or more from the 5’ end of any gene, (ii) 300 kb or more from any gene related to cancer, (iii) 300 kb or more from any microRNA(miRNA), (iv) located outside a transcription unit and (v) located outside ultra-conserved regions (UCR). It may not be necessary to satisfy all of these proposed criteria, since GSH already identified do not fulfil all of the criteria. It is thought that a suitable GSH will satisfy at least 2, 3, 4 or all of these criteria.
- the first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene.
- the first and further genomic safe harbour sites are located on chr1 : 152,360,840-152,360,859, chr1 : 175,942,362 -175,942,381 , chr1 :231 ,999,396-231 ,999,415, chr2: 45,708,354 - 45, 708, 373; chr8: 68,720,172 - 68,720,191 of the human genome.
- the first and further genomic safe harbour sites are selected from any two of the bovine safe harbour sites ROSA26, AAVS1 , the CLYBL gene and the CCR5 gene.
- the genetic safe harbour sites are hROSA26 locus and the AAVS1 locus.
- the expression construct for expression of PPAR- y protein as described herein and the expression construct for expression of a CEBPa protein as described herein are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site.
- the expression construct that is inserted into the second genetic safe harbour site is capable of expressing both the PPAR-y protein and the CEBPa protein simultaneously.
- pluripotent stem cells includes embryonic stem cells, embryo- derived stem cells, induced pluripotent stem cells and somatic cells, regardless of the method by which the pluripotent stem cells are derived. Accordingly, in certain embodiments the pluripotent stem cell is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, embryonic cell lines, and somatic cell lines. In certain embodiments, the pluripotent stem cells are epiblast-derived stem cells (EpiSC).
- EpiSC epiblast-derived stem cells
- pluripotent stem cells express one or more markers selected from the group consisting of: OCT-4, Sox2, Klf4, c-MYC, Nanog, Lin28, alkaline phosphatase, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81.
- Exemplary pluripotent stem cells can be generated using, methods known in the art.
- “Induced pluripotent stem cells” iPS cells or iPSC) can be produced by protein transduction of reprogramming factors in a somatic cell.
- the pluripotent stem cell according to the invention can be from any species. Embryonic stem cells have been successfully derived in, for example, mice, multiple species of non-human primates, and humans, and embryonic stem-like cells have been generated from numerous additional species. Thus, one of skill in the art can generate embryonic stem cells and embryo- derived stem cells from any species, including but not limited to, human, non-human primates, rodents (mice, rats), ungulates (cows, sheep, etc.), dogs (domestic and wild dogs), cats (domestic and wild cats such as lions, tigers, cheetahs), rabbits, hamsters, gerbils, squirrel, guinea pig, goats, elephants, panda (including giant panda), pigs, raccoon, horse, zebra, marine mammals (dolphin, whales, etc.) and the like.
- iPS cells can be from any species. These iPS cells have been successfully generated using mouse and human cells. Furthermore, iPS cells have been successfully generated using embryonic, fetal, newborn, and adult tissue. Accordingly, one can readily generate iPS cells using a donor cell from any species.
- the pluripotent stem cell according to the invention, or for use in the invention is an animal cell. In certain embodiments the pluripotent stem cell according to the invention, or for use in the invention if from an edible animal species.
- the pluripotent stem cell according to the invention is from a livestock or poultry animal.
- Livestock species include but are not limited to domestic cattle, pigs, sheep, goats, lamb, camels, water buffalo and rabbits.
- the pluripotent stem cell according to the invention is a porcine or a bovine pluripotent stem cell. Most preferably, a porcine pluripotent stem cell.
- the stem cell according to the invention is a porcine epiblast stem cell (pEpiSCs).
- Poultry species include but are not limited to domestic chicken, turkeys, ducks, geese and pigeons.
- the cells originate from common game species such as wild deer, gallinaceous fowl, waterfowl and hare.
- a pluripotent stem cell according to the invention, or for use in the invention is not a human cell.
- Transcriptional repressor proteins bind to a response element and prevent gene expression.
- Transcriptional regulator proteins may be activated or deactivated by a number of mechanisms including binding of a substance, interaction with other transcription factors (e.g., homo- or hetero-dimerization) or coregulatory proteins, phosphorylation, and/or methylation.
- the transcriptional regulator may be controlled by activation or deactivation.
- the transcriptional regulator protein is a transcriptional activator protein
- the transcriptional activator protein requires activation. This activation may be through any suitable means, but it is preferred that the transcriptional regulator protein is activated through the addition to the cell of an exogenous substance.
- the supply of an exogenous substance to the cell can be controlled, and thus the activation of the transcriptional regulator protein can be controlled.
- an exogenous substance can be supplied in order to deactivate a transcriptional regulator protein, and then supply withdrawn in orderto activate the transcriptional regulator protein.
- the transcriptional regulator protein is a transcriptional repressor protein
- it is preferred that the transcriptional repressor protein requires deactivation.
- a substance is supplied to prevent the transcriptional repressor protein repressing transcription, and thus transcription is permitted.
- transcriptional regulator protein Any suitable transcriptional regulator protein may be used, preferably one that is activatable or deactivatable. It is preferred that an exogenous substance may be supplied to control the transcriptional regulator protein. Such transcriptional regulator proteins are also called inducible transcriptional regulator proteins. Accordingly, in certain embodiments, the pluripotent stem cell according to the invention is controlled by an exogenously supplied substance.
- the exogenously supplied substance is selected from the group consisting of peptides (such as described by Klotzsche, et al; Journal of Biological Chemistry 280.26 (2005): 24591-24599 or Schlicht et al.; Applied and environmental microbiology 72.8 (2006): 5637- 5642) or the inducers described in Goeke, et al. Journal of molecular biology 416.1 (2012): 33-45; incorporated herein by reference), an aptamer (such as the RNA aptamer described in Hunsicker et al. “Chemistry & biology 16.2 (2009): 173-180; incorporated herein by reference), tetracycline, and anhydroteracyclin or a derivative thereof.
- the exogenously supplied substance is doxycycline.
- the transcriptional regulator protein as described herein is selected from the group consisting of tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor or an activation domain from the human NF-kB.
- rtTa tetracycline responsive transcriptional activator protein
- TetR Tetracycline repressor
- VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor or an activation domain from the human NF-kB.
- Tetracycline-Controlled Transcriptional Activation is a method of inducible gene expression well known in the art where transcription is reversibly turned on or off in the presence of the antibiotic tetracycline or one of its derivatives (e.g. doxycycline which is more stable).
- the transcriptional activator protein is tetracycline - responsive transcriptional activator protein (rtTa) ora derivative thereof.
- the rtTA protein is able to bind to DNA at specific TetO operator sequences.
- Several repeats of such TetO sequences are placed upstream of a minimal promoter (such as the CMV promoter), which together form a tetracycline response element (TRE).
- TRE tetracycline response element
- Tet-Off tetracycline or a derivative thereof binds rTA and deactivates the rTA, rendering it incapable of binding to TRE sequences, thereby preventing transcription of TRE- controlled genes.
- the Tet-On system is composed of two components; (1) the constitutively expressed tetracycline - responsive transcriptional activator protein (rtTa) and the rtTa sensitive inducible promoter (Tet Responsive Element, TRE). This may be bound by tetracycline or its more stable derivatives, including doxycycline (dox), resulting in activation of rtTa, allowing it to bind to TRE sequences and inducing expression of TRE-controlled genes.
- the transcriptional regulator protein is rtTA.
- the inducible promoter inserted into the at least one further GSH hat is not the first GSH site includes the tetracycline response element (TRE).
- the inducible promoter includes a Tet Responsive Element (TRE).
- the transcriptional regulator protein is rtTA and includes TRE the exogenously supplied substance is the antibiotic tetracycline or one of its derivatives.
- the expression construct that is inserted into the second genetic safe harbour site is a fusion protein that encodes both the PPAR-y protein and the CEBPa protein as described herein.
- expression construct that is inserted into the second genetic safe harbour site encodes a PPAR-y protein a linker and a CEBPa protein, in preferred embodiments, the construct comprises or consists of SEQ ID NO: 4.
- the linker sequence may be a cleavable linker. That is, the linker sequence may comprise a sequence of amino acids which is capable of being cleaved.
- the linker sequence may comprise a sequence capable of acting as a substrate for an enzyme capable of cleaving peptide bonds--i.e. a cleavage site. Many such cleavage sites are known to and can be employed by the person skilled in the art of molecular biology.
- the cleavable linker may comprise an autocleavage site. Autocleavage sites are automatically cleaved without the need for treatment with enzymes.
- 2A self-cleaving peptides or 2A peptides have been described, which includes 2A peptides P2A, E2A, F2A, and T2A.
- F2A is derived from foot-and-mouth disease virus
- E2A is derived from equine rhinitis A virus
- P2A is derived from porcine teschovirus-1 2A
- T2A is derived from thosea asigna virus 2A.
- the cleavable linker is thus selected from the group consisting of P2A, E2A, F2A, and T2A.
- the expression construct comprises a Picornavirus 2A (P2A) linker.
- the expression construct comprises a linker comprising or consisting of the sequence of SEQ ID NO: 3.
- the expression construct that is inserted into the second genetic safe harbour site encoding a PPAR-y protein a linker and a CEBPa protein as described herein comprises or consists of the sequence of SEQ ID NO: 4.
- the inducible promotor that is operably linked to the PPAR-y protein is different than the inducible promotor that is linked to the CEBPa protein. In certain embodiments, the inducible promotor that is operably linked to the PPAR-y protein is the same at the inducible promotor that is linked to the CEBPa protein.
- Inducible promotors are well-known in the art, examples include but are not limited to CMV, CAG, CBh, PGK, SV40, Ferritin heavy or light chains, etc.
- the inducible promotor used in the present invention a tetOn promotor.
- a tetOn promotor Preferably a 3 rd generation TetOn promotor.
- the invention relates to a method for the production of adipocytes, comprising a ) culturing the pluripotent stem cell as described herein in a proliferation medium: followed by b) inducing adipocyte differentiation by adding an exogenous substance as described herein.
- the method of the invention is an ex vivo method. In certain embodiments, the method is for the production of mature adipocytes. Mature adipocytes are herein defined as adipocytes which show lipid accumulation and/or express detectable levels of PPARy FABP4, PLIN1 and adiponectin.
- the method of the invention relates to a method for production of white adipocytes.
- the proliferation and/or differentiation medium does not comprise or does not substantially comprise at least one compound selected from the group of insulin dexamethasone, rosiglitazone and isobutylmethylxanthine. In preferred embodiments, the proliferation and/or differentiation medium does not comprise or does not substantially comprise insulin.
- a proliferation and/or differentiation medium which does not comprise or does not substantially comprise insulin may optionally comprise IGF-1 and/or LR3.
- a proliferation and/or differentiation medium may comprise up to about 20 pg/mL insulin, for example up to about 10 pg/mL insulin, such as about 5 pg/mL insulin, for example 1 pg/mL insulin”.
- the inventors have surprisingly found that use of the pluripotent cell as described herein obviates the need to culture the cells with a commitment induction step.
- the commitment or determination phase involves the formation of preadipocytes, which have lost the potential to differentiate into other cell types. Differentiation of preadipocytes to adipocytes is promoted by a highly regulated network of transcription factors chronologically expressed to promote adipocyte morphologic and biochemical features such as insulin responsiveness, lipid transport and synthesis, and secretory capacity.
- the differentiation phase is also divided into four stages: growth arrest, mitotic clonal expansion, early differentiation, and terminal differentiation.
- pluripotent stem cells as described herein allows the differentiation of the pluripotent stem cells to mature adipocytes without needing a commitment induction step and without forcing overexpression.
- the ability of the cells to skip this commitment induction step is particularly advantageous as it reduces the amount of compounds and small molecules that are normally required to be present in the differentiation medium. It was for example found that the cells as described herein are able to differentiate without the presence of BMP-4, Activin A and FGF2 which are normally required for satisfactory differentiation. The ability to leave out these compounds and small molecules from the differentiation medium reduces the medium costs and eases the way to regulatory acceptance.
- differentiation phase and differentiation stage are used interchangeably herein.
- the method as described herein does not comprise an additional commitment phase induction step.
- the method as described herein reduces the differentiation time of the pluripotent cells as described herein to mature adipocytes dramatically.
- the time to produce mature adipocytes using the method as claimed is at most 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days or 2 days.
- the inventors have observed a conversion rate of at least 95% by day 4 of culture, meaning that at least 95% of the cells are mature after 4 days of culture. Accordingly, in certain embodiments the time to produce at least 95% mature adipocytes is at most 4 days.
- the invention provides for adipocytes, preferably mature adipocytes, as obtained by the method as described herein.
- Culturing the cells as described herein can be performed under so called 2D culturing conditions, which is considered the conventional approach to culturing cells.
- the method as described can also easily be adapted to allow culturing under 3D conditions as shown in the examples below.
- 3D cell culture is an artificially-created environment which enables cells to grow or interact with their surroundings in three dimensions.
- cells typically form 3D colonies, which may be referred to as "spheroids".
- the 3D culture approach may more accurately model the cells' in vivo growth and behaviour.
- the skilled person is readily able to carry out 3D cell culture, for example by taking advantage of any of a number of commercially-available culturing tools.
- the 3D culture may be carried out using scaffold or scaffold-free techniques. Scaffoldbased techniques make use of supports such as solid scaffolds and hydrogels to enable the cells to form a 3D culture.
- Such scaffolds may aim to mimic the natural extracellular matrix (ECM), which is present in vivo.
- ECM extracellular matrix
- 3D spheroids may be established through the use of, for example, low-adhesion plates, hanging-drop plates, micro-patterned surfaces, rotating bioreactors, magnetic levitation and magnetic 3D bioprinting.
- the adipocytes that are produced according to the method as disclosed herein are for human and non-human dietary consumption.
- the produced adipocytes can be used in the production of cultured meat for human consumption.
- the invention provides for a use of a pluripotent stem cell as described herein or the adipocytes obtained by the method as described herein for tissue engineering.
- the method as described herein is for ex vivo or in vivo tissue engineering.
- the use is for the production of cultured meat. That is to say, the invention provides for a use of a pluripotent stem cell as described herein or the adipocytes obtained by the method as described herein for the production of cultured meat.
- the invention provides for a food product (also referred to as “foodstuff’) comprising the pluripotent stem cells as described herein or the adipocytes produced and/or obtained by the method as described.
- the food product is or further comprises an edible composition for human or non-human consumption.
- the edible composition for human or non-human consumption for example comprises at least one of myocytes, mature muscle cells, minerals, synthetic substances, flavoring substances (such as for examples herbs and spices), plant based proteins or proteins from microbial origin such as yeast proteins. Plant based proteins and yeast proteins suitable for the use in food products are known to the skilled person in the art.
- the food product is cultured meat or a cultured meat product.
- the invention provides for a method of producing a food product, the method comprising combining the pluripotent stem cells as described herein or the produced and/or obtained adipocytes with an edible composition for human consumption or non-human consumption as described herein.
- the food product is cultured meat.
- Figure 1 Comparison between EpiSCs-PPARy and EpiSCs-PPARy-CEBPa 2D differentiation. Undifferentiated (day 0) and differentiated (days 2, 4, 6 and 8) EpiSCs-PPARy and EpiSCs CEBPa- PPARy. Bright-field microscopy, 10X.
- Figure 2 mRNA relative gene expression for porcine PPARy and CEBPa Opti-Ox cells.
- Figure 3 Total intracellular triglycerides quantification for undifferentiated EpiSCs-PPARy and EpiSCs-PPARy-CEBPa and after 2, 4, 6 and 8 days of differentiation.
- Figure 4 Comparison between EpiSCs-PPARy and EpiSCs-PPARy-CEBPa 2D differentiation. Undifferentiated (day 0) and differentiated (days 7, 14 and 20). Fluorescent microscopy, 10X. Stained with Oil Red O (red, neutral lipids) and DAPI (blue, nuclei).
- Figure 5 Comparison between EpiSCs-PPARy and EpiSCs-PPARy-CEBPa 3D differentiation. EpiSCs-PPARy and EpiSCs PPARy-CEBPa differentiated in suspension (3D, day 6) stained with Oil Red O (red, neutral lipids) and DAPI (blue, nuclei). Fluorescent microscopy, 10X.
- Figure 6 EpiSCs PPARy-CEBPa differentiated (days 4, 12 and 20) under protocol D (Mesodermal step+Maturation step) or protocol F (only maturation step).
- Figure 7 EpiSCs PPARy-CEBPa differentiated (days 2, 7 and 13) under protocol D (Mesodermal step+Maturation step) with maturation media supplemented with (1) KSR, insulin and dexamethasone (2) KSR and dexamethasone or (3) KSR and insulin; or under protocol F (only maturation step) with maturation media supplemented according to conditions (1), (2) and (3). Bright-field microscopy, 20X.
- Figure 8 EpiSCs PPARy-CEBPa differentiated in suspension (3D, day 13) under protocol D (Mesodermal step+Maturation step) with maturation media supplemented with (1) KSR, insulin and dexamethasone (2) KSR and dexamethasone or (3) KSR and insulin; or under protocol F (only maturation step) with maturation media supplemented according to conditions (1), (2) and (3). Aggregates stained with Oil Red O (red, neutral lipids) and DAPI (blue, nuclei). Fluorescent microscopy, 10X.
- Figure 9 EpiSCs PPARy-CEBPa differentiated in suspension (3D, day 7) in a bioreactor under a fed batch protocol that is similar to protocol D (Mesodermal step+Maturation step) with media supplemented with insulin and dexamethasone. Aggregates were collected on day 0, 3, 5 and 7 of differentiation and total intracellular triglycerides quantified.
- FIG. 10 EpiSCs PPARy-CEBPa differentiated (day 7) under protocol F (only maturation step) with maturation media supplemented with insulin at (A) 20 pg/mL, (B) 10 pg/mL, (C) 5 pg/mL or (D) without insulin. Maturation media was also supplemented with (E) 0,05 pg/mL IGF-1 or (F) 0,05 pg/mL IGF-1/LR3 in the absent of insulin. Bright-field microscopy, 20X.
- Porcine Epiblast-derived Stem Cells (pEplSCs) differentiation to adipocytes.
- Undifferentiated pEplSCs (Opti-Ox PPARy and Opti-Ox CEBPa-PPARy) were grown in N2B27 proliferation media (50% DMEM Ham’s F-12 (L0093-500, Biowest), 50% Neurobasal media (21103049, Thermofisher), B27 supplement (17504044, Thermofisher), N2 supplement (17502001 , Thermofisher), glutamax (35050061 , Thermofisher), 10 mM 2-Mercaptoethanol (31350010, Thermofisher), 0,02pg/mL Activin A (QK001 , Q-kine), 0,10 pg/mL FGF2 (QK002, Q-kine), 0,625 pg/mL XAV939 (X3004, Sigma Aldrich) on hESC-qualified geltrex (A1413301 .Thermo Scientific) - coated plates.
- N2B27 proliferation media 50% DMEM Ham’s
- Single cells were obtained after gentle cell dissociation reagent (07174, STEMCELL technologies) treatment and cell number and viability were assessed.
- Single pEplSCs cells were seeded in the corresponding cell culture plates at a density of 50000-150000 cells/cm2.
- adipocyte maturation media composed by DMEM Ham’s F-12 (L0093-500, Biowest) containing 15% Knockout Serum Replacement (10828-028, Thermofisher), 1 pg/mL insulin (12585014, Thermofisher) and 1 pM Dexamethasone (D1756, Sigma Adrich).
- pEplSCs were differentiated for the specified amount of days. Media was refreshed every two days. Doxycycline (1 pg/mL, D9891 , Sigma Aldrich) was added to the differentiation media to activate the Opti-OX system in these cells.
- undifferentiated single-pEplSCs (Opti-Ox PPARy and Opti-Ox CEBPa-PPARy) were seeded at 3 million cells/mL in 250 mL shaker flasks containing 25 mL of proliferation media (containing 50% DMEM Ham’s F-12 (L0093-500, Biowest), 50% Neurobasal media (21 103049, Thermofisher), B27 supplement (17504044, Thermofisher), N2 supplement (17502001 , Thermofisher), glutamax (35050061 , Thermofisher), 10 mM 2- Mercaptoethanol (31350010, Thermofisher) , 0,02pg/mL Activin A (QK001 , Q-kine), 0,10 pg/mL FGF2 (QK002, Q-kine), 0,625 pg/mL XAV939 (X3004, Sigma Aldrich), 2X %
- Undifferentiated and differentiated pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy were stained with Oil Red O as previously described (00625, Sigma). Briefly, cells in culture or in aggregates were washed with phosphate buffered saline (PBS) and fixed with 4 paraformaldehyde (PFA) for 40 minutes at room temperature. After being washed 3 times with PBS and permeabilized with 60% isopropanol, cells were stained with Oil Red O (0,5% in isopropanol) diluted to 40% with water, for 30 minutes at room temperature.
- PBS phosphate buffered saline
- PFA paraformaldehyde
- pEplSCs were washed several times with deionized water until only lipid droplets were properly stained with the dye. Undifferentiated and differentiated cells were photographed under a inverted bright fieldlight microscope (Oxion Inverso, Euromex) or under fluorescent microcopya (EVOS M7000, Thermo Fisher Scientific). Triglyceride content of pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa- PPARy was estimated at different check points during adipogenesis by extracting Oil Red O dye from the cells with 100% isopropanol and measuring spectrophotometrically the resulting solution at 540 mM (Glomax Discover, Promega).
- Oil Red O data were adjusted by an estimation of the number of cells spectrophotometrically measured by HOESCH 33342 staining (H1399, Thermo Fisher Scientific), according to the manufacturer’s instructions.
- pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy differentiated in aggregates or spheroids were stained following the same protocol previously described. Two different approaches were followed for imaging acquisition. For a quick check on adipocyte quality, stained aggregates were transferred to a slide. After removing excess buffer, the slides were coverslipped using hard set mounting medium (P36984, Thermo Fisher Scientific).
- the spheroid aggregates are flattened, resulting in an overview of lipid presence and an estimate of its distribution.
- unstained and fixed cell aggregates were cryopreserved in sucrose solution.
- the frozen samples were then sectioned at 20 pm with a cryostat (CM 1950, Leica).
- the cryosections were stained using the Oil Red O staining protocol previously described. Measurements included total cell number, total lipid number per cell, lipid size and shape, total intensity (within lipid objects).
- Intracellular triglyceride content was quantified from undifferentiated and differentiated cultured/aggregates pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy using Triglyceride Quantification Colorimetric/Fluorometric Kit (MAK266-1 KT, Sigma Aldrich) according to manufacturer's instructions. Briefly, total lipids were extracted with 5% Nonidet P40 Substitute (11754599001 , Sigma Aldrich) solution in deionized water under heating.
- glycerol was released from triglycerides and subsequently reacted to generate colour, which can be measured spectrophotometrically at 570nm (Glomax Discover, Promega). TG concentrations were calculated based upon a standard curve made from TG standards and normalized to total cellular protein content.
- RNA from undifferentiated and differentiated pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy was extracted using Reliaprep Cell Miniprep System (Z6012, Promega) according to the manufacturer's instructions. RNA concentration and quality was determined with a Microvolume Spectrophotometer DS-11 (DeNovix). Five hundred nanograms of purified total RNA from every sample were first treated with DNase I to remove possible genomic DNA contamination and were subsequently reverse transcribed into cDNA using iScript gDNA Clear cDNA Synthesis Kit (1725035BUN, BioRad).
- pEpiSCs PPARg fat accumulation and cell morphology were far from being comparable to porcine mature adipocytes and some specific late adipogenesis markers, such as PLIN1 or Adiponectin, were not expressed even after 21 days of differentiation.
- PPARg and CEBPa were selected for used in a combined cellular reprogramming strategy.
- a knock-in that has PPARg, a P2A “self-cleaving” peptide linker and CEBPa all in one open reading frame to simultaneously express PPARg and CEBPa by doxycycline induction.
- 2A peptide linkers are well-characterized short peptide linkers of 18-22 amino acids that result in two separate gene products expressed from a single open reading frame due to ribosome skipping during translation.
- Stable knock-ins in the AAVS1 GSH were selected by incorporation of a puromycin-resistance cassette and selected with puromycin addition to the cell culture medium. Following selection, single pEpiSC cells were plated and clonal cell lines were isolated for outgrowth and analysis. Incorporation of doxycycline-inducible PPARg-P2A- CEBPa was subsequently confirmed using PCR genomic analysis, Sanger sequencing and RT- qPCR. Using the dual GSH-targeting approach, we selected clonal lines that carried two copies of each of the transgenes, and observed that homozygous targeting of both elements allowed inducible overexpression (data not shown). Importantly, the dual GSH-targeting approach did not affect SC self-renewal or differentiation as determined by RT-qPCR (data not shown).
- Example 2 EpiSCs-PPARy-CEBPa 2D short-term differentiation into adipocytes.
- pEpiSCs Opti-Ox PPARy and pEpiSCs Opti-Ox PPARy-CEBPa were differentiated with doxycycline for up to 8 days. Pictures were taken from the undifferentiated cells (day 0) and during differentiation (at days 2, 4, 6 and 8) using bright-field microscopy.
- pEplSCs comprising Opti-Ox -PPARy-CEBPa created bigger lipid droplets during differentiation than pEpiSC PPARy indicating better cell maturation and more lipid accumulation. This difference was already visible at day 4 after the start of differentiation indicating a much more rapid differentiation for pEplSCs comprising Opti-Ox PPARy-CEBPa.
- pEpiSC PPARy-CEBPa cells express Opti-Ox CEBPa and Opti-Ox PPARy, already after 2 days of differentiation, which confirms that the Opti-Ox system is capable of stable transgene expression and confirms the useability of the cell model.
- pEpiSC PPARy-CEBPa cells had higher expression of several adipocyte markers (LPL and CD36, Perilipin 1 (indicating lipid accumulation), CEBP6 and ZBTB16 (late adipogenesis markers), Adiponectin and FABP4 (markers of terminal cell differentiation). Adiponectin and Perilipin 1 were not expressed in the pEpiSC PPARy.
- Example 3 EpiSCs-PPARy-CEBPa 2D long-term differentiation into adipocytes.
- pEpiSC PPARy-CEBPa cells do not need to reach confluency before starting differentiation (data not shown) indicating that pEpiSC PPARy-CEBPa are less dependent of external pro-adipogenic factors (ECM, secreted factors).
- ECM pro-adipogenic factors
- Protocol D including commitment +maturation step
- protocol F only maturation step
- Cells were collected during differentiation at days 4, 12 and 20 and analyzed under bright-field microscopy ( Figure 6A). Neutral lipid content was estimated by Oil Red O adjusted by the number of cells measured with the HOESCH method. Both dyes were spectrophotometrically quantified ( Figure 6B).
- Example 5 EpiSCs-PPARy-CEBPa 2D differentiation: Differentiation using protocol D and protocol F with KSR+lnsulin+Dexamethasone, with KSR+Dexamethasone (no extra insulin) and with KSR+ Insulin (No Dexamethasone).
- EpiSCs-PPARy-CEBPa need additional insulin and dexamethasone in the maturation step of differentiation
- EpiSCs-PPARy-CEBPa were differentiated in 2D using differentiation protocols D and F in the presence or absence of additional insulin and/or dexamethasone.
- Cells were collected during differentiation at days 2, 7 and 13 and analyzed under bright-field microscopy (Figure 7A).
- Adipogenesis performance was comparable between both Protocol D and F with insulin and dexamethasone and these protocols without insulin and/or dexamethasone. Being able to leave out insulin and dexamethasone makes this model more promising in terms cost-reduction (process and media) and because several small molecules can be left out for regulatory acceptance of cultivated meat.
- Example 6 3D culture of EpiSCs-PPARy-CEBPa
- suspension culture of cells in 3D is a necessary step to scale up to large volumes and generate the amounts of adipocytes needed for a cultivated meat product at cost competitive prices (for example in shakers and/or bioreactors).
- suspension culture of cells in 3D allows the cells to grow in an environment that more closely mimics the physiological in vivo environment of the cells the transition from 2D to 3D culture needs to be properly performed and differentiation data obtained from 2D experiments need to be validated in 3D.
- EpiSCs-PPARy-CEBPa were adapted to 3D suspension cell growth and grown as aggregates; EpiSCs-PPARy-CEBPa expanded in an adherent 6-well cell plate were single celled with Accumax (00-4666-56, ThermoFisher Scientific) according to the manufacturer’s instructions and transferred to a 150 mL shaker flask in 12,5mL media and a RHO/ROCK pathway inhibitor and thereafter expanded for at least 3 cycles. Media during expansion in 3D was refreshed daily. 3D adapted EpiSCs-PPARy-CEBPa were subsequently used in shaker and bioreactor experiments.
- Example 7 EpiSCs-PPARy-CEBPa 3D differentiation in suspension-. Protocol optimization: Differentiation using protocol D and protocol F with KSR+lnsulin+Dexamethasone, with KSR+Dexamethasone (no extra insulin) and with KSR+ Insulin (No Dexamethasone).
- EpiSCs-PPARy- CEBPa were differentiated in shakers and the setup of example 5 was repeated in 3D.
- pEpiSC PPARy-CEBPa differentiated both, under the protocol D (mesodermal step+maturation step) and the protocol F (only maturation step) in 3D in suspension as well ( Figure 8).
- I ntracellular triglycerides were also detectable in the center of the aggregate which points to a sufficient nutrient and factor perfusion inside of the 3D structure (including size aggregate).
- pEpiSC PPARy-CEBPa are also capable of differentiation into adipocytes with no additional insulin and with no dexamethasone added in the maturation media, again confirming this model is more promising in terms costreduction (process and media) and because several small molecules can be left out for regulatory acceptance of cultivated meat.
- Example 8 EpiSCs-PPARy-CEBPa 3D differentiation in suspension in bioreactor:
- pEpiSC PPARy-CEBPa can be grown and differentiated in a bioreactor
- a fed batch procedure was designed using an Ambr250 modular bioreactor system (Sartorius), where 6x10 6 /mL undifferentiated cells were inoculated in 120mL DMEMF/12 medium (21041-025, Gibco) supplemented with KSR, BMP4, FGF2, Activin A, Glutamax and Ascorbic acid in the same concentrations described for previous experiments.
- Glucose concentration was maintained above 7 mM, temperature was kept at physiological levels, agitation speed was sufficient to assure aggregate size do not exceed the limits for nutrient perfusion, 7,5% Sodium bicarbonate was added on demand to maintain pH at 7,4 ⁇ 0,5 and dissolved oxygen set-point was established between 30-70%. Additional insulin and doxycycline were added on days 0, 2, 4 and 6 while dexamethasone was only added once on day 2. Aggregates were collected on day 0, 3, 5 and 7 of differentiation for further analysis. Media components concentrations were monitored every 24 hours to identify possible limitations (data not shown). Samples for neutral lipid quantification and gene expression analysis were obtained on days 0, 3, 5 and 7. Aggregate’s size were measured on day 0 and 6.
- PPARy-CEBPa pEplSCs were seeded at 125000 cells/cm2 in 6-well plates pre-coated with Geltrex, in proliferation media + Fasudil at 3.5pM. Cells were homogeneously distributed in the wells and incubated overnight at 38.5 degrees, 5% CO2 to ensure their attachment.
- Adipocyte differentiation was induced the next day by refreshing the media with maturation media (Protocol F) supplemented with 0.5 pg/mL doxycycline and containing 20 pg/mL insulin (control, condition Figure 10A), 10 pg/mL insulin (condition Figure 10B), 5 pg/mL insulin (condition Figure 10C) or in the absence of insulin (condition Figure 10D).
- maturation media Protocol F
- Free-insulin maturation media was also supplemented with 0.05 pg/mL IGF-1 (Condition Figure 10E) and 0.05 pg/mL IGF-1/LR3 (condition Figure 10F). Maturation media was replaced every two days and cells were incubated at 38.5 degrees, 5% CO2 during differentiation. Bright-field images were taken on day 8 of differentiation. These results confirm that insulin is not required for efficient differentiation.
- the present invention provides at least the following numbered statements/embodiments:
- a pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR- y protein, wherein the coding sequence for the PPAR- y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter; wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
- a pluripotent stem cell according to embodiment 1 wherein the expression constructs of ii) and iii) are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site.
- the pluripotent stem cell according to embodiment 1 or 2 wherein the cell is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, embryonic cell lines, and somatic cell lines.
- pluripotent stem cell according to any one of embodiments 1 -3, wherein the pluripotent stem cells are of a livestock or poultry species.
- pluripotent stem cell according to embodiment 4, wherein the livestock species is porcine or bovine, preferably porcine.
- the pluripotent stem cell according to any one of embodiments 2-5, wherein the expression construct that is inserted into the second genetic safe harbour site encodes a PPAR- y protein a linker and a CEBPa protein, preferably wherein the linker is P2A, more preferably wherein the linker comprises the sequence of SEQ ID NO: 3.
- the transcriptional regulator protein is selected from the group consisting of: tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor and an activation domain from the human NF-kB, preferably the transcriptional regulator protein is rtTA.
- rtTa tetracycline responsive transcriptional activator protein
- TetR Tetracycline repressor
- VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor and an activation domain from the human NF-kB, preferably the transcriptional regulator protein is rtTA.
- the inducible promotor is a tetON promotor.
- the pluripotent stem cell according to any one of embodiments 1-11 wherein said first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene, preferably wherein the genetic safe harbour site are hROSA26 locus and the AAVS1 locus.
- a method for the production of adipocytes comprising a ) culturing the pluripotent stem cell according to any one of the preceding claims in a proliferation medium: followed by b) inducing adipocyte differentiation by adding the exogenous substance according to claim 8, preferably the proliferation and/or differentiation medium does not comprise insulin and/or dexamethasone.
- a food product comprising the pluripotent stem cell according to any one of embodiments 1-12 or the adipocytes obtained by the method according to any one of claims 13-15.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- High Energy & Nuclear Physics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of producing adipocytes comprising the pluripotent stem cells and for foodstuff comprising the adipocytes or pluripotent stem cells.
Description
Adipocyte maturation
Field of the invention
The present invention relates to modified pluripotent cells and to methods of differentiating said cell into adipocytes.
Background of the invention
According to the most recent United Nations estimations, the current world population is 7.9 billion in July 2022 [https://www.worldometers.info/es/poblacion-mundial/#ref-1] and it is expected to reach 10 billion around the year 2056. This increase will be heterogeneously distributed around the globe, with nine countries covering half the projected growth of the global population in the next 30 years, including India, Nigeria, Pakistan, Egypt, and the United States of America. Population and economic growth are major drivers of increased meat consumption. According to the United Nations Food and Agricultural Organization (FAO, https://www.oecd- ilibrary.org/agriculture-and-food/oecd-fao-agricultural-outlook-2022-2031_f1 b0b29c-en), an estimated growth of 15% in global meat consumption is projected by 2031 . On the other hand, the correlation between income growth and higher meat consumption is clearly demonstrable at lower income rates but once consumers reach an adequate standard of living, they become more sensitive to environmental, ethical, and animal welfare and health concerns.
For this reason, there is a growing interest in finding alternative protein sources which ideally will be sustainable and will contain the nutrients normally provided by meat in the human diet. Cultured meat arises as another alternative to traditional animal agriculture that aims to produce the skeletal muscle and adipose tissues that normally comprise animal meats, except using in vitro tissue and biological engineering techniques. Despite efforts to develop robust protocols for scalable generation of animal cell types from easily accessible and renewable sources, the differentiation of animal (pluripotent) stem cells into specific cell types often remains cumbersome, lengthy, and difficult to reproduce and/or has not been established yet.
Additionally, to date, plant-based and cultured meat alternatives have focused mostly on mimicking the muscle component of meat. However, fat is also a crucial component of meat, contributing to sensory/ flavor, textural attributes and palatability (Zhang, Shu, et al. "DNA polymorphisms in bovine fatty acid synthase are associated with beef fatty acid composition 1." Animal genetics 39.1 (2008): 62-70.).
Modified cell lines that can be differentiated to adipocytes have been previously described by Tontonoz et al (Cell, Vol. 79, 1147-1156 - 30 -12- 1994) wherein a retroviral expression system is used to co-express PPARy and CEBPa into a fibroblast cell line upon which spontaneous differentiation to adipocytes was observed. US2012219530 describes lentivirally transduced human pluripotent cells that have a differentiation efficiency of about 20%. However these protocols have several limitation including heterogeneous adipocyte degree of maturation, lack of scalable process, are not food safe and have long cultivation times of up to 28 days.
Accordingly there remains a need in the art for the production and culturing of mature adipocytes that are suitable for human consumption and that can be produced in a scalable and cost effective manner.
Summary of the invention
In a first aspect, the invention relates to a pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR-y protein, wherein the coding sequence for the PPAR-y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter; wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
In certain embodiments of the invention, the expression constructs of ii) and iii) are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site. Preferably, said first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene, preferably wherein the genetic safe harbour site are hROSA26 locus and the AAVS1 locus.
In certain embodiments of the invention, the cell is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, embryonic cell lines, and somatic cell lines.
In certain embodiments of the invention, the pluripotent stem cells are of a livestock or poultry species. Preferably, the livestock species is porcine or bovine, preferably porcine. The pluripotent stem cells may be of the family Suidae, for example the genus Sus, such as the species S. domesticus.
In certain embodiments of the invention, the expression construct that is inserted into the second genetic safe harbour site encodes a PPAR-y protein a linker and a CEBPa protein, preferably wherein the linker is P2A, more preferably wherein the linker comprises the sequence of SEQ ID NO: 3. Preferably, the construct comprises the sequence of SEQ ID NO: 4.
In certain embodiments of the invention, the activity of the transcriptional regulator protein is controlled by an exogenously supplied substance derivative. Preferably, the transcriptional regulator protein is selected from the group consisting of: tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor and an activation domain from the human NF-kB, preferably the transcriptional regulator protein is rtTA.
In certain embodiments, the inducible promoter includes a Tet Responsive Element (TRE).
In certain embodiments, the inducible promotor is a tetON promotor.
In a second aspect the invention provides for a method for the production of adipocytes, preferably white adipocytes, comprising a ) culturing the pluripotent stem cell according to any one of the preceding claims in a proliferation medium: followed by b) inducing adipocyte differentiation by adding the exogenous substance as described herein.
In certain embodiments, the proliferation and/or differentiation medium does not comprise or does not substantially comprise at least one compound selected from the group of insulin, dexamethasone, rosiglitazone and isobutylmethylxanthine. In certain preferred embodiments, the proliferation and/or differentiation medium does not comprise or does not substantially comprise insulin. A proliferation and/or differentiation medium which does not comprise or does not substantially comprise insulin may optionally comprise IGF-1 and/or LR3.
In certain embodiments, the differentiation phase of the method as described herein is at most 10 days, at most 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days or 2 days .
In certain embodiments, the produced adipocytes are for human and non-human dietary consumption.
In a further aspect, the invention provides for a use of a pluripotent stem cell as described herein or use of the method for producing a adipocyte as described herein for tissue engineering, optionally for the production of cultured meat.
In yet a further aspect, the invention provides for a food product comprising the pluripotent stem cell as described herein or the adipocytes obtained by the method as described herein. In certain embodiments, the food product is cultured meat.
Description of the invention
Definitions
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the method.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".
As used herein, the term "and/or" indicates that one or more of the stated cases may occur, alone or in combination with at least one of the stated cases, up to with all of the stated cases.
As used herein, with "At least" a particular value means that particular value or more. For example, "at least 2" is understood to be the same as "2 or more" i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, ... ,etc.
The word “about” or “approximately” when used in association with a numerical value (e.g. about 10) preferably means that the value may be the given value (of 10) more or less 0.1 % of the value.
The term "heterologous" when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature. Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins that are not normally produced by the cell in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is present. Heterologous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous nucleic acid or protein. The term heterologous also applies to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
The terms "expression vector" or “expression construct" refer to nucleotide sequences that are capable of effecting expression of a gene in host cells or host organisms compatible with such sequences. These expression vectors typically include at least suitable transcription regulatory sequences and optionally, 3' transcription termination signals. Additional factors necessary or helpful in effecting expression may also be present, such as expression enhancer elements
As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For instance, a transcription regulatory sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein encoding regions, contiguous and in reading frame, inducible promoter
As used herein, the term "promoter" refers to a nucleic acid fragment that functions to control the transcription of one or more coding sequences, and is located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A "constitutive" promoter is a promoter that is active in most tissues under most physiological and developmental conditions. An "inducible" promoter is a promoter that
is physiologically or developmentally regulated, e.g. by the application of a chemical inducer. In the case of the present invention, the control is effected by the transcriptional regulator protein.
Any reference to nucleotide or amino acid sequences accessible in public sequence databases herein refers to the version of the sequence entry as available on the filing date of this document.
All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
The inventors have surprisingly found that the time period required for differentiation of pluripotent cells into mature adipocytes can dramatically be reduced by using a modified pluripotent stem cells that comprise an expression construct for expression of a PPAR-y protein and an expression construct for expression of a CEBPa protein. As shown in the examples described herein, by using these modified pluripotent cell lines, full differentiation into mature adipocytes can be achieved in less than 10 days. Apart from significantly reducing the culturing time and the associated cost involved, the use of the herein describe pluripotent cells also provides for a more reliable and scalable production of mature adipocyte as compared to what has been previously described.
Accordingly, in a first aspect the invention relates to a pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR-y protein, wherein the coding sequence for the PPAR-y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter; wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
Peroxisome proliferator- activated receptor gamma (PPAR-y) is a type II nuclear receptor functioning as a transcription factor that in humans is encoded by the PPARG gene. PPARG is mainly present in adipose tissue, colon and macrophages. Two isoforms of PPARG are detected in the human and in the mouse: PPAR-y1 (found in nearly all tissues except muscle) and PPAR-y2 (mostly found in adipose tissue and the intestine). In certain embodiments, the coding sequence of PPAR-y of the invention encodes PPAR-y2. PPARG regulates fatty acid storage and glucose metabolism. The genes activated by PPARG stimulate lipid uptake and adipogenesis by fat cells. PPARG knockout mice are devoid of adipose tissue, establishing PPARG as a master regulator of adipocyte differentiation. In certain embodiments, the coding sequence for the PPAR-y has the sequence of SEQ ID NO: 1 .
CCAAT/enhancer-binding protein alpha (CEBPa) is a protein encoded by the CEBPA gene in humans. The protein encoded by this intronless gene is a bZIP transcription factor which can
bind as a homodimer to certain promoters and gene enhancers. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma, as well as distinct transcription factors such as c-Jun. The encoded protein is a key regulator of adipogenesis (the process of forming new fat cells) and the accumulation of lipids in those cells, as well as in the metabolism of glucose and lipids in the liver. In certain embodiments, the coding sequence for the CEBPa has the sequence of SEQ ID NO: 2.
In certain embodiments, the nucleic acid molecules encoding the proteins according to the invention are codon-optimized for expression in mammalian cells. Methods of codon-optimization are known and have been described previously (e.g. WO 96/09378 for mammalian cells). A sequence is considered codon-optimized if at least one non-preferred codon as compared to a wildtype sequence is replaced by a codon that is more preferred. Herein, a non-preferred codon is a codon that is used less frequently in an organism than another codon coding for the same amino acid, and a codon that is more preferred is a codon that is used more frequently in an organism than a non-preferred codon. The frequency of codon usage for a specific organism can be found in codon frequency tables, such as in http://www.kazusa.or.jp/codon. Preferably more than one nonpreferred codon, preferably most or all non-preferred codons, are replaced by codons that are more preferred. Preferably the most frequently used codons in an organism are used in a codon- optimized sequence. Replacement by preferred codons generally leads to higher expression.
A transcriptional regulator protein is a protein that bind to DNA, preferably sequence- specifically to a DNA site located in or near a promoter, and either facilitating the binding of the transcription machinery to the promoter, and thus transcription of the DNA sequence (a transcriptional activator) or blocks this process (a transcriptional repressor). Such entities are also known as transcription factors.
The DNA sequence that a transcriptional regulator protein binds to is called a transcription factor-binding site or response element, and these are found in or nearthe promoter of the regulated DNA sequence.
Transcriptional activator proteins bind to a response element and promote gene expression. Such proteins are preferred in the methods of the present invention for controlling inducible cassette expression.
A genetic safe harbour (GSH) site is a locus within the genome wherein a gene or other genetic material may be inserted without any deleterious effects on the cell or on the inserted genetic material. Most beneficial is a GSH site in which expression of the inserted gene sequence is not perturbed by any read-through expression from neighboring genes and expression of the inducible cassette minimizes interference with the endogenous transcription program. More formal criteria have been proposed that assist in the determination of whether a particular locus is a GSH site in future (Papapetrou et al, 2011 , Nature Biotechnology, 29(1), 73-8. doi: 1 0. 1 038/nbt. 1 71 7.) These criteria include a site that is (i) 50 kb or more from the 5’ end of any gene, (ii) 300 kb or more from any gene related to cancer, (iii) 300 kb or more from any microRNA(miRNA), (iv) located outside a transcription unit and (v) located outside ultra-conserved regions (UCR). It may not be
necessary to satisfy all of these proposed criteria, since GSH already identified do not fulfil all of the criteria. It is thought that a suitable GSH will satisfy at least 2, 3, 4 or all of these criteria.
In certain embodiments of the invention, the first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene. In certain embodiments the first and further genomic safe harbour sites are located on chr1 : 152,360,840-152,360,859, chr1 : 175,942,362 -175,942,381 , chr1 :231 ,999,396-231 ,999,415, chr2: 45,708,354 - 45, 708, 373; chr8: 68,720,172 - 68,720,191 of the human genome.
In certain embodiments of the invention, the first and further genomic safe harbour sites are selected from any two of the bovine safe harbour sites ROSA26, AAVS1 , the CLYBL gene and the CCR5 gene.
Preferably, the genetic safe harbour sites are hROSA26 locus and the AAVS1 locus.
In certain embodiments of the invention, the expression construct for expression of PPAR- y protein as described herein and the expression construct for expression of a CEBPa protein as described herein are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site. In certain embodiments, the expression construct that is inserted into the second genetic safe harbour site is capable of expressing both the PPAR-y protein and the CEBPa protein simultaneously.
As used herein, the term "pluripotent stem cells" includes embryonic stem cells, embryo- derived stem cells, induced pluripotent stem cells and somatic cells, regardless of the method by which the pluripotent stem cells are derived. Accordingly, in certain embodiments the pluripotent stem cell is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, embryonic cell lines, and somatic cell lines. In certain embodiments, the pluripotent stem cells are epiblast-derived stem cells (EpiSC). In certain embodiments, pluripotent stem cells express one or more markers selected from the group consisting of: OCT-4, Sox2, Klf4, c-MYC, Nanog, Lin28, alkaline phosphatase, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. Exemplary pluripotent stem cells can be generated using, methods known in the art. "Induced pluripotent stem cells" (iPS cells or iPSC) can be produced by protein transduction of reprogramming factors in a somatic cell.
The pluripotent stem cell according to the invention can be from any species. Embryonic stem cells have been successfully derived in, for example, mice, multiple species of non-human primates, and humans, and embryonic stem-like cells have been generated from numerous additional species. Thus, one of skill in the art can generate embryonic stem cells and embryo- derived stem cells from any species, including but not limited to, human, non-human primates, rodents (mice, rats), ungulates (cows, sheep, etc.), dogs (domestic and wild dogs), cats (domestic and wild cats such as lions, tigers, cheetahs), rabbits, hamsters, gerbils, squirrel, guinea pig, goats, elephants, panda (including giant panda), pigs, raccoon, horse, zebra, marine mammals (dolphin, whales, etc.) and the like.
Similarly, iPS cells can be from any species. These iPS cells have been successfully generated using mouse and human cells. Furthermore, iPS cells have been successfully generated using embryonic, fetal, newborn, and adult tissue. Accordingly, one can readily generate iPS cells
using a donor cell from any species. Thus, one can generate iPS cells from any species, including but not limited to, human, non-human primates, rodents (mice, rats), ungulates (cows, sheep, etc.), dogs (domestic and wild dogs), cats (domestic and wild cats such as lions, tigers, cheetahs), rabbits, hamsters, goats, elephants, panda (including giant panda), pigs, raccoon, horse, zebra, marine mammals (dolphin, whales, etc.) and the like.
In certain embodiments, the pluripotent stem cell according to the invention, or for use in the invention is an animal cell. In certain embodiments the pluripotent stem cell according to the invention, or for use in the invention if from an edible animal species.
Preferably, the pluripotent stem cell according to the invention, or for use in the invention is from a livestock or poultry animal. Livestock species include but are not limited to domestic cattle, pigs, sheep, goats, lamb, camels, water buffalo and rabbits.
Preferably, the pluripotent stem cell according to the invention, or for use in the invention is a porcine or a bovine pluripotent stem cell. Most preferably, a porcine pluripotent stem cell. In certain embodiments, the stem cell according to the invention is a porcine epiblast stem cell (pEpiSCs).
Poultry species include but are not limited to domestic chicken, turkeys, ducks, geese and pigeons. In certain embodiments, the cells originate from common game species such as wild deer, gallinaceous fowl, waterfowl and hare. Preferably a pluripotent stem cell according to the invention, or for use in the invention, is not a human cell.
Transcriptional repressor proteins bind to a response element and prevent gene expression.
Transcriptional regulator proteins may be activated or deactivated by a number of mechanisms including binding of a substance, interaction with other transcription factors (e.g., homo- or hetero-dimerization) or coregulatory proteins, phosphorylation, and/or methylation. The transcriptional regulator may be controlled by activation or deactivation.
If the transcriptional regulator protein is a transcriptional activator protein, it is preferred that the transcriptional activator protein requires activation. This activation may be through any suitable means, but it is preferred that the transcriptional regulator protein is activated through the addition to the cell of an exogenous substance. The supply of an exogenous substance to the cell can be controlled, and thus the activation of the transcriptional regulator protein can be controlled. Alternatively, an exogenous substance can be supplied in order to deactivate a transcriptional regulator protein, and then supply withdrawn in orderto activate the transcriptional regulator protein.
If the transcriptional regulator protein is a transcriptional repressor protein, it is preferred that the transcriptional repressor protein requires deactivation. Thus, a substance is supplied to prevent the transcriptional repressor protein repressing transcription, and thus transcription is permitted.
Any suitable transcriptional regulator protein may be used, preferably one that is activatable or deactivatable. It is preferred that an exogenous substance may be supplied to control the transcriptional regulator protein. Such transcriptional regulator proteins are also called inducible transcriptional regulator proteins.
Accordingly, in certain embodiments, the pluripotent stem cell according to the invention is controlled by an exogenously supplied substance.
In certain embodiments, the exogenously supplied substance is selected from the group consisting of peptides (such as described by Klotzsche, et al; Journal of Biological Chemistry 280.26 (2005): 24591-24599 or Schlicht et al.; Applied and environmental microbiology 72.8 (2006): 5637- 5642) or the inducers described in Goeke, et al. Journal of molecular biology 416.1 (2012): 33-45; incorporated herein by reference), an aptamer (such as the RNA aptamer described in Hunsicker et al. “Chemistry & biology 16.2 (2009): 173-180; incorporated herein by reference), tetracycline, and anhydroteracyclin or a derivative thereof. Preferably, the exogenously supplied substance is doxycycline.
In certain embodiments, the transcriptional regulator protein as described herein is selected from the group consisting of tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor or an activation domain from the human NF-kB.
Tetracycline-Controlled Transcriptional Activation is a method of inducible gene expression well known in the art where transcription is reversibly turned on or off in the presence of the antibiotic tetracycline or one of its derivatives (e.g. doxycycline which is more stable). In this system, the transcriptional activator protein is tetracycline - responsive transcriptional activator protein (rtTa) ora derivative thereof. The rtTA protein is able to bind to DNA at specific TetO operator sequences. Several repeats of such TetO sequences are placed upstream of a minimal promoter (such as the CMV promoter), which together form a tetracycline response element (TRE). There are two forms of this system, depending on whether the addition of tetracycline or a derivative activates (Tet-On) or deactivates (Tet-Off) the rTA protein.
In a Tet-Off system, tetracycline or a derivative thereof binds rTA and deactivates the rTA, rendering it incapable of binding to TRE sequences, thereby preventing transcription of TRE- controlled genes. The Tet-On system is composed of two components; (1) the constitutively expressed tetracycline - responsive transcriptional activator protein (rtTa) and the rtTa sensitive inducible promoter (Tet Responsive Element, TRE). This may be bound by tetracycline or its more stable derivatives, including doxycycline (dox), resulting in activation of rtTa, allowing it to bind to TRE sequences and inducing expression of TRE-controlled genes. In preferred embodiments of the invention the transcriptional regulator protein is rtTA.
If the transcriptional regulator protein is rtTA, then the inducible promoter inserted into the at least one further GSH hat is not the first GSH site includes the tetracycline response element (TRE). Thus, in certain embodiments the inducible promoter includes a Tet Responsive Element (TRE).
In some embodiments, where the transcriptional regulator protein is rtTA and includes TRE the exogenously supplied substance is the antibiotic tetracycline or one of its derivatives.
In certain embodiments of the invention, the expression construct that is inserted into the second genetic safe harbour site is a fusion protein that encodes both the PPAR-y protein and the CEBPa protein as described herein. In certain embodiments, expression construct that is inserted
into the second genetic safe harbour site encodes a PPAR-y protein a linker and a CEBPa protein, in preferred embodiments, the construct comprises or consists of SEQ ID NO: 4.
In certain embodiments, the linker sequence may be a cleavable linker. That is, the linker sequence may comprise a sequence of amino acids which is capable of being cleaved. For example, the linker sequence may comprise a sequence capable of acting as a substrate for an enzyme capable of cleaving peptide bonds--i.e. a cleavage site. Many such cleavage sites are known to and can be employed by the person skilled in the art of molecular biology. In some embodiments, the cleavable linker may comprise an autocleavage site. Autocleavage sites are automatically cleaved without the need for treatment with enzymes. For example the family of 2A self-cleaving peptides, or 2A peptides have been described, which includes 2A peptides P2A, E2A, F2A, and T2A. F2A is derived from foot-and-mouth disease virus; E2A is derived from equine rhinitis A virus; P2A is derived from porcine teschovirus-1 2A; T2A is derived from thosea asigna virus 2A. In certain embodiments, the cleavable linker is thus selected from the group consisting of P2A, E2A, F2A, and T2A.
In some preferred embodiments the expression construct comprises a Picornavirus 2A (P2A) linker. Preferably, the expression construct comprises a linker comprising or consisting of the sequence of SEQ ID NO: 3.
In certain embodiments, the expression construct that is inserted into the second genetic safe harbour site encoding a PPAR-y protein a linker and a CEBPa protein as described herein comprises or consists of the sequence of SEQ ID NO: 4.
In certain embodiments, the inducible promotor that is operably linked to the PPAR-y protein is different than the inducible promotor that is linked to the CEBPa protein. In certain embodiments, the inducible promotor that is operably linked to the PPAR-y protein is the same at the inducible promotor that is linked to the CEBPa protein. Inducible promotors are well-known in the art, examples include but are not limited to CMV, CAG, CBh, PGK, SV40, Ferritin heavy or light chains, etc.
In certain embodiments, the inducible promotor used in the present invention a tetOn promotor. Preferably a 3rd generation TetOn promotor.
Culturing methods
The inventors of present application have surprisingly found that the differentiation time needed to obtain adipocytes can dramatically be reduced by using the pluripotent cells as described herein. Accordingly, in a further aspect the invention relates to a method for the production of adipocytes, comprising a ) culturing the pluripotent stem cell as described herein in a proliferation medium: followed by b) inducing adipocyte differentiation by adding an exogenous substance as described herein.
In certain embodiments, the method of the invention is an ex vivo method.
In certain embodiments, the method is for the production of mature adipocytes. Mature adipocytes are herein defined as adipocytes which show lipid accumulation and/or express detectable levels of PPARy FABP4, PLIN1 and adiponectin.
In certain embodiments, the method of the invention relates to a method for production of white adipocytes. In certain embodiments, the proliferation and/or differentiation medium does not comprise or does not substantially comprise at least one compound selected from the group of insulin dexamethasone, rosiglitazone and isobutylmethylxanthine. In preferred embodiments, the proliferation and/or differentiation medium does not comprise or does not substantially comprise insulin.
A proliferation and/or differentiation medium which does not comprise or does not substantially comprise insulin may optionally comprise IGF-1 and/or LR3.
A proliferation and/or differentiation medium may comprise up to about 20 pg/mL insulin, for example up to about 10 pg/mL insulin, such as about 5 pg/mL insulin, for example 1 pg/mL insulin”.
The inventors have surprisingly found that use of the pluripotent cell as described herein obviates the need to culture the cells with a commitment induction step. Normally, when adipocytes are cultured several culturing phases can be distinguished. The commitment or determination phase involves the formation of preadipocytes, which have lost the potential to differentiate into other cell types. Differentiation of preadipocytes to adipocytes is promoted by a highly regulated network of transcription factors chronologically expressed to promote adipocyte morphologic and biochemical features such as insulin responsiveness, lipid transport and synthesis, and secretory capacity. The differentiation phase is also divided into four stages: growth arrest, mitotic clonal expansion, early differentiation, and terminal differentiation. Use of the pluripotent stem cells as described herein in the method as described herein allows the differentiation of the pluripotent stem cells to mature adipocytes without needing a commitment induction step and without forcing overexpression. The ability of the cells to skip this commitment induction step is particularly advantageous as it reduces the amount of compounds and small molecules that are normally required to be present in the differentiation medium. It was for example found that the cells as described herein are able to differentiate without the presence of BMP-4, Activin A and FGF2 which are normally required for satisfactory differentiation. The ability to leave out these compounds and small molecules from the differentiation medium reduces the medium costs and eases the way to regulatory acceptance. The term differentiation phase and differentiation stage are used interchangeably herein.
Accordingly, in certain embodiments the method as described herein does not comprise an additional commitment phase induction step.
The method as described herein reduces the differentiation time of the pluripotent cells as described herein to mature adipocytes dramatically. In certain embodiments, the time to produce mature adipocytes using the method as claimed is at most 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days or 2 days. Using the pluripotent cells as described in the method as described, the inventors have observed a conversion rate of at least 95% by day 4 of culture,
meaning that at least 95% of the cells are mature after 4 days of culture. Accordingly, in certain embodiments the time to produce at least 95% mature adipocytes is at most 4 days.
In a further aspect, the invention provides for adipocytes, preferably mature adipocytes, as obtained by the method as described herein.
Culturing the cells as described herein can be performed under so called 2D culturing conditions, which is considered the conventional approach to culturing cells. However, the method as described can also easily be adapted to allow culturing under 3D conditions as shown in the examples below.
3D cell culture is an artificially-created environment which enables cells to grow or interact with their surroundings in three dimensions. In such culture, cells typically form 3D colonies, which may be referred to as "spheroids". The 3D culture approach may more accurately model the cells' in vivo growth and behaviour. The skilled person is readily able to carry out 3D cell culture, for example by taking advantage of any of a number of commercially-available culturing tools. For example, the 3D culture may be carried out using scaffold or scaffold-free techniques. Scaffoldbased techniques make use of supports such as solid scaffolds and hydrogels to enable the cells to form a 3D culture. Such scaffolds may aim to mimic the natural extracellular matrix (ECM), which is present in vivo. Scaffold-free techniques dispense with the use of the scaffold on which to grow the cells. Instead, 3D spheroids may be established through the use of, for example, low-adhesion plates, hanging-drop plates, micro-patterned surfaces, rotating bioreactors, magnetic levitation and magnetic 3D bioprinting.
Cells that have been transduced with lentiviral vectors are not considered food safe or not safe for human and non-human dietary consumption. The pluripotent cells as described herein of the method as described herein obviates the need to use lentivirally transduced cells. Accordingly, in certain embodiments, the adipocytes that are produced according to the method as disclosed herein are for human and non-human dietary consumption. In certain embodiments, the produced adipocytes can be used in the production of cultured meat for human consumption.
In a further aspect, the invention provides for a use of a pluripotent stem cell as described herein or the adipocytes obtained by the method as described herein for tissue engineering. In certain embodiments the method as described herein is for ex vivo or in vivo tissue engineering.
In certain aspect, the use is for the production of cultured meat. That is to say, the invention provides for a use of a pluripotent stem cell as described herein or the adipocytes obtained by the method as described herein for the production of cultured meat.
In yet a further aspect, the invention provides for a food product (also referred to as “foodstuff’) comprising the pluripotent stem cells as described herein or the adipocytes produced and/or obtained by the method as described. In certain embodiments, the food product is or further comprises an edible composition for human or non-human consumption. The edible composition for human or non-human consumption for example comprises at least one of myocytes, mature muscle cells, minerals, synthetic substances, flavoring substances (such as for examples herbs and spices), plant based proteins or proteins from microbial origin such as yeast proteins. Plant based proteins and yeast proteins suitable for the use in food products are known to the skilled
person in the art. In certain embodiments, the food product is cultured meat or a cultured meat product.
In yet a further aspect, the invention provides for a method of producing a food product, the method comprising combining the pluripotent stem cells as described herein or the produced and/or obtained adipocytes with an edible composition for human consumption or non-human consumption as described herein. In certain embodiments, the food product is cultured meat.
Description of the sequences
Description of the figures
Figure 1 : Comparison between EpiSCs-PPARy and EpiSCs-PPARy-CEBPa 2D differentiation. Undifferentiated (day 0) and differentiated (days 2, 4, 6 and 8) EpiSCs-PPARy and EpiSCs CEBPa- PPARy. Bright-field microscopy, 10X.
Figure 2: mRNA relative gene expression for porcine PPARy and CEBPa Opti-Ox cells. A) PPARy, B) CEBPa, C) endogenous PPARy D) endogenous CEBPa E) adiponectin, F) LPL, G) Perilipin-1 , H) FABP4, i) CD36 and J) CEBPp , K) ZBTB16 and L) Oct 4 . EpiSCs-PPARy and EpiSCs CEBPa- PPARy differentiated in 2D for 8 days.
Figure 3: Total intracellular triglycerides quantification for undifferentiated EpiSCs-PPARy and EpiSCs-PPARy-CEBPa and after 2, 4, 6 and 8 days of differentiation.
Figure 4: Comparison between EpiSCs-PPARy and EpiSCs-PPARy-CEBPa 2D differentiation. Undifferentiated (day 0) and differentiated (days 7, 14 and 20). Fluorescent microscopy, 10X. Stained with Oil Red O (red, neutral lipids) and DAPI (blue, nuclei).
Figure 5: Comparison between EpiSCs-PPARy and EpiSCs-PPARy-CEBPa 3D differentiation. EpiSCs-PPARy and EpiSCs PPARy-CEBPa differentiated in suspension (3D, day 6) stained with Oil Red O (red, neutral lipids) and DAPI (blue, nuclei). Fluorescent microscopy, 10X.
Figure 6: EpiSCs PPARy-CEBPa differentiated (days 4, 12 and 20) under protocol D (Mesodermal step+Maturation step) or protocol F (only maturation step). A) Bright-field microscopy, 40X. B) Quantification (absorbance) of the intracellular Oil Red O staining extracted from EpiSCs CEBPa- PPARy differentiated for 20 days under protocol D or protocol F conditions.
Figure 7: EpiSCs PPARy-CEBPa differentiated (days 2, 7 and 13) under protocol D (Mesodermal step+Maturation step) with maturation media supplemented with (1) KSR, insulin and dexamethasone (2) KSR and dexamethasone or (3) KSR and insulin; or under protocol F (only maturation step) with maturation media supplemented according to conditions (1), (2) and (3). Bright-field microscopy, 20X.
Figure 8: EpiSCs PPARy-CEBPa differentiated in suspension (3D, day 13) under protocol D (Mesodermal step+Maturation step) with maturation media supplemented with (1) KSR, insulin and dexamethasone (2) KSR and dexamethasone or (3) KSR and insulin; or under protocol F (only maturation step) with maturation media supplemented according to conditions (1), (2) and (3). Aggregates stained with Oil Red O (red, neutral lipids) and DAPI (blue, nuclei). Fluorescent microscopy, 10X.
Figure 9: EpiSCs PPARy-CEBPa differentiated in suspension (3D, day 7) in a bioreactor under a fed batch protocol that is similar to protocol D (Mesodermal step+Maturation step) with media supplemented with insulin and dexamethasone. Aggregates were collected on day 0, 3, 5 and 7 of differentiation and total intracellular triglycerides quantified.
Figure 10: EpiSCs PPARy-CEBPa differentiated (day 7) under protocol F (only maturation step) with maturation media supplemented with insulin at (A) 20 pg/mL, (B) 10 pg/mL, (C) 5 pg/mL or (D) without insulin. Maturation media was also supplemented with (E) 0,05 pg/mL IGF-1 or (F) 0,05 pg/mL IGF-1/LR3 in the absent of insulin. Bright-field microscopy, 20X.
Examples
The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.
Materials and Methods
Porcine Epiblast-derived Stem Cells (pEplSCs) differentiation to adipocytes.
Undifferentiated pEplSCs (Opti-Ox PPARy and Opti-Ox CEBPa-PPARy) were grown in N2B27 proliferation media (50% DMEM Ham’s F-12 (L0093-500, Biowest), 50% Neurobasal media
(21103049, Thermofisher), B27 supplement (17504044, Thermofisher), N2 supplement (17502001 , Thermofisher), glutamax (35050061 , Thermofisher), 10 mM 2-Mercaptoethanol (31350010, Thermofisher), 0,02pg/mL Activin A (QK001 , Q-kine), 0,10 pg/mL FGF2 (QK002, Q-kine), 0,625 pg/mL XAV939 (X3004, Sigma Aldrich) on hESC-qualified geltrex (A1413301 .Thermo Scientific) - coated plates. For 2D adipocyte differentiation, single cells were obtained after gentle cell dissociation reagent (07174, STEMCELL technologies) treatment and cell number and viability were assessed. Single pEplSCs cells were seeded in the corresponding cell culture plates at a density of 50000-150000 cells/cm2. After an overnight incubation in proliferation media with 10 pm Rock Inhibitor (Y-27632 (HBF2297, HelloBio), cells were cultivated in StemPro-34 SFM media (10639011 , Thermo Scientific) supplemented with 25 ng/mL Activin A (120-14E, PeproTech), 10 ng/mL BMP4 (120-05ET, PeproTech), 4 ng/mL FGF2 (Qk002, Qkine) and 50 mg/mL Ascorbic acid (A8960, Sigma Aldrich) for 48 hours to enhance stem cells commitment to adipocyte lineage. On day 2, media was replaced by adipocyte maturation media composed by DMEM Ham’s F-12 (L0093-500, Biowest) containing 15% Knockout Serum Replacement (10828-028, Thermofisher), 1 pg/mL insulin (12585014, Thermofisher) and 1 pM Dexamethasone (D1756, Sigma Adrich). pEplSCs were differentiated for the specified amount of days. Media was refreshed every two days. Doxycycline (1 pg/mL, D9891 , Sigma Aldrich) was added to the differentiation media to activate the Opti-OX system in these cells.
For spheroids or aggregates differentiation experiments, undifferentiated single-pEplSCs (Opti-Ox PPARy and Opti-Ox CEBPa-PPARy) were seeded at 3 million cells/mL in 250 mL shaker flasks containing 25 mL of proliferation media (containing 50% DMEM Ham’s F-12 (L0093-500, Biowest), 50% Neurobasal media (21 103049, Thermofisher), B27 supplement (17504044, Thermofisher), N2 supplement (17502001 , Thermofisher), glutamax (35050061 , Thermofisher), 10 mM 2- Mercaptoethanol (31350010, Thermofisher) , 0,02pg/mL Activin A (QK001 , Q-kine), 0,10 pg/mL FGF2 (QK002, Q-kine), 0,625 pg/mL XAV939 (X3004, Sigma Aldrich), 2X % Knockout Serum Replacement (10828-028, Thermofisher)KSR and 10ng/mLX FGF2). Next day, once small spheroids were formed, media was replaced by supplemented StemPro-34 SFM. In the same way, maturation media was added at day 2 of differentiation and was refreshed every two days until the end of the experiment.
Oil Red O Staining
Undifferentiated and differentiated pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy were stained with Oil Red O as previously described (00625, Sigma). Briefly, cells in culture or in aggregates were washed with phosphate buffered saline (PBS) and fixed with 4 paraformaldehyde (PFA) for 40 minutes at room temperature. After being washed 3 times with PBS and permeabilized with 60% isopropanol, cells were stained with Oil Red O (0,5% in isopropanol) diluted to 40% with water, for 30 minutes at room temperature. Thereafter, pEplSCs were washed several times with deionized water until only lipid droplets were properly stained with the dye.
Undifferentiated and differentiated cells were photographed under a inverted bright fieldlight microscope (Oxion Inverso, Euromex) or under fluorescent microcopya (EVOS M7000, Thermo Fisher Scientific). Triglyceride content of pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa- PPARy was estimated at different check points during adipogenesis by extracting Oil Red O dye from the cells with 100% isopropanol and measuring spectrophotometrically the resulting solution at 540 mM (Glomax Discover, Promega). Oil Red O data were adjusted by an estimation of the number of cells spectrophotometrically measured by HOESCH 33342 staining (H1399, Thermo Fisher Scientific), according to the manufacturer’s instructions. pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy differentiated in aggregates or spheroids were stained following the same protocol previously described. Two different approaches were followed for imaging acquisition. For a quick check on adipocyte quality, stained aggregates were transferred to a slide. After removing excess buffer, the slides were coverslipped using hard set mounting medium (P36984, Thermo Fisher Scientific). In this process the spheroid aggregates are flattened, resulting in an overview of lipid presence and an estimate of its distribution. For a more accurate analysis, unstained and fixed cell aggregates were cryopreserved in sucrose solution. The frozen samples were then sectioned at 20 pm with a cryostat (CM 1950, Leica). The cryosections were stained using the Oil Red O staining protocol previously described. Measurements included total cell number, total lipid number per cell, lipid size and shape, total intensity (within lipid objects).
Triglyceride content
Intracellular triglyceride content was quantified from undifferentiated and differentiated cultured/aggregates pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy using Triglyceride Quantification Colorimetric/Fluorometric Kit (MAK266-1 KT, Sigma Aldrich) according to manufacturer's instructions. Briefly, total lipids were extracted with 5% Nonidet P40 Substitute (11754599001 , Sigma Aldrich) solution in deionized water under heating. By adding lipase, glycerol was released from triglycerides and subsequently reacted to generate colour, which can be measured spectrophotometrically at 570nm (Glomax Discover, Promega). TG concentrations were calculated based upon a standard curve made from TG standards and normalized to total cellular protein content.
Real-time quantitative PCR analysis (RT-qPCR)
Total RNA from undifferentiated and differentiated pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox CEBPa-PPARy was extracted using Reliaprep Cell Miniprep System (Z6012, Promega) according to the manufacturer's instructions. RNA concentration and quality was determined with a Microvolume Spectrophotometer DS-11 (DeNovix). Five hundred nanograms of purified total RNA from every sample were first treated with DNase I to remove possible genomic DNA contamination and were subsequently reverse transcribed into cDNA using iScript gDNA Clear cDNA Synthesis Kit (1725035BUN, BioRad). Specific primers for porcine pluripotency and mature adipocyte markers
were designed to perform real-time quantitative PCR analysis (table I). At least three samples from two independent experiments were amplified in triplicates in an (thermocycler) system using PowerTrack SYBR Green Master Mix (A461 12, Thermofisher) according to manufacturer’s guidelines. RT-qPCR conditions were 95 °C for 30 seconds, followed by 40 cycles of of 15 s at 95°C and 1 min at 60°C. The YWHAZ gene was used as a housekeeping gene to normalize the target gene expression levels. Relative gene quantification was calculated by the 2-AACt method.
Results
Example 1: Development of an Inducible Transgene Overexpression Method by Dual GSH Targeting in Animal Cells
To explore the potential of OPTi-OX for forward programming of porcine (pPSCs), we generated PPARG OPTi-OX pPSCs. We sequentially targeted the rtTA cassette into the porcine ROSA26 GSH under control of a CAG promoter and a PPARG transgene into the porcine AAVS1 GSH under control of a doxycycline-inducible element and observed robust and homogeneous inducible transgene expression. Induction of PPARG expression following dox treatment resulted in cells accumulating lipids. These findings demonstrated that PPARG overexpression alone was sufficient to drive adipogenesis in pPSCs. However, pEpiSCs PPARg fat accumulation and cell morphology were far from being comparable to porcine mature adipocytes and some specific late adipogenesis markers, such as PLIN1 or Adiponectin, were not expressed even after 21 days of differentiation.
After conducting a systematic screen for adipogenic factors by modulating key signaling cascades that are implicated in adipogenesis, PPARg and CEBPa were selected for used in a combined cellular reprogramming strategy. We designed a knock-in that has PPARg, a P2A “self-cleaving” peptide linker and CEBPa all in one open reading frame to simultaneously express PPARg and CEBPa by doxycycline induction. 2A peptide linkers are well-characterized short peptide linkers of 18-22 amino acids that result in two separate gene products expressed from a single open reading frame due to ribosome skipping during translation. Stable knock-ins in the AAVS1 GSH were selected by incorporation of a puromycin-resistance cassette and selected with puromycin addition to the cell culture medium. Following selection, single pEpiSC cells were plated and clonal cell lines were isolated for outgrowth and analysis. Incorporation of doxycycline-inducible PPARg-P2A- CEBPa was subsequently confirmed using PCR genomic analysis, Sanger sequencing and RT- qPCR. Using the dual GSH-targeting approach, we selected clonal lines that carried two copies of each of the transgenes, and observed that homozygous targeting of both elements allowed inducible overexpression (data not shown). Importantly, the dual GSH-targeting approach did not affect SC self-renewal or differentiation as determined by RT-qPCR (data not shown).
Example 2: EpiSCs-PPARy-CEBPa 2D short-term differentiation into adipocytes. pEpiSCs Opti-Ox PPARy and pEpiSCs Opti-Ox PPARy-CEBPa were differentiated with doxycycline for up to 8 days. Pictures were taken from the undifferentiated cells (day 0) and during
differentiation (at days 2, 4, 6 and 8) using bright-field microscopy. As can be seen in Figure 1 , pEplSCs comprising Opti-Ox -PPARy-CEBPa created bigger lipid droplets during differentiation than pEpiSC PPARy indicating better cell maturation and more lipid accumulation. This difference was already visible at day 4 after the start of differentiation indicating a much more rapid differentiation for pEplSCs comprising Opti-Ox PPARy-CEBPa.
We used RT-qPCR to assess mRNA relative gene expression for porcine endogenous PPARy, CEBPa, adiponectin, LPL, Perilipin-1 , FABP4, CD36 and CEBP6, results are shown in Figure 2.
As expected, pEpiSC PPARy-CEBPa cells express Opti-Ox CEBPa and Opti-Ox PPARy, already after 2 days of differentiation, which confirms that the Opti-Ox system is capable of stable transgene expression and confirms the useability of the cell model. pEpiSC PPARy-CEBPa cells had higher expression of several adipocyte markers (LPL and CD36, Perilipin 1 (indicating lipid accumulation), CEBP6 and ZBTB16 (late adipogenesis markers), Adiponectin and FABP4 (markers of terminal cell differentiation). Adiponectin and Perilipin 1 were not expressed in the pEpiSC PPARy. Indicating that pEpiSC PPARy-CEBPa have a higher differentiation potential. Additionally, we observed that Oct4 expression is induced in pEpiSC PPARy-CEBPa at day 2. This effect is not observed in pEpiSC PPARy. Oct4 is known to be an important modulator for the commitment of the cells to the adipocyte lineage indicating that the pEpiSC PPARy-CEBPa do not need a commitment step during differentiation which allows for quicker differentiation.
Next, we quantified the total triglyceride content from the undifferentiated and differentiated cells (Figure 3) using Oil Red O staining. Oil Red O is a fat-soluble dye that stains neutral triglycerides and lipids. The results show that pEpiSC PPARy-CEBPa had a significantly higher triglyceride content indicating that their differentiation is faster and more efficient when compared to pEpiSC PPARy.
Example 3: EpiSCs-PPARy-CEBPa 2D long-term differentiation into adipocytes.
We repeated the experiment from example 2 but now differentiated the pEplSCs Opti-Ox PPARy and pEplSCs Opti-Ox PPARy-CEBPa cells for up to 20 days and collected the differentiated cells at Day 7, 14 and 21 for Oil Red O Staining (Figure 4). pEpiSC CEBPa-PPARy cells accumulates bigger lipid droplets than pEpiSC PPARy during adipogenesis. The difference is already detectable at day 7, with the pEplSCs Opti-Ox PPARy-CEBPa having a well-defined adipocyte-like shape and homogenous lipid accumulation. Additionally, pEpiSC PPARy-CEBPa cells do not need to reach confluency before starting differentiation (data not shown) indicating that pEpiSC PPARy-CEBPa are less dependent of external pro-adipogenic factors (ECM, secreted factors).
Example 4: EpiSCs-PPARy-CEBPa skip the commitment step during differentiation
To confirm that a commitment differentiation step was not required EpiSCs-PPARy-CEBPa were differentiated in 2D using two differentiation protocols. Protocol D (including commitment
+maturation step) and protocol F (only maturation step). Cells were collected during differentiation at days 4, 12 and 20 and analyzed under bright-field microscopy (Figure 6A). Neutral lipid content was estimated by Oil Red O adjusted by the number of cells measured with the HOESCH method. Both dyes were spectrophotometrically quantified (Figure 6B).
While the commitment step was necessary to improve the differentiation capacity of the pEpiSC PPARy (data not shown), EpiSCs-PPARy-CEBPa adipogenesis performance was comparable between protocol D and F (Figure 6A). As a matter of fact, neutral lipid accumulation per cell was higher in the EpiSCs-PPARy-CEBPa differentiated in the absence of the mesodermal step (Figure 6B), which makes this model more promising in terms of cost- reduction (process and media) and because several small molecules can be left out for regulatory acceptance of cultured meat.
Example 5: EpiSCs-PPARy-CEBPa 2D differentiation: Differentiation using protocol D and protocol F with KSR+lnsulin+Dexamethasone, with KSR+Dexamethasone (no extra insulin) and with KSR+ Insulin (No Dexamethasone).
To explore if EpiSCs-PPARy-CEBPa need additional insulin and dexamethasone in the maturation step of differentiation, EpiSCs-PPARy-CEBPa were differentiated in 2D using differentiation protocols D and F in the presence or absence of additional insulin and/or dexamethasone. Cells were collected during differentiation at days 2, 7 and 13 and analyzed under bright-field microscopy (Figure 7A). Adipogenesis performance was comparable between both Protocol D and F with insulin and dexamethasone and these protocols without insulin and/or dexamethasone. Being able to leave out insulin and dexamethasone makes this model more promising in terms cost-reduction (process and media) and because several small molecules can be left out for regulatory acceptance of cultivated meat.
Example 6: 3D culture of EpiSCs-PPARy-CEBPa
In suspension culture of cells in 3D is a necessary step to scale up to large volumes and generate the amounts of adipocytes needed for a cultivated meat product at cost competitive prices (for example in shakers and/or bioreactors). Although in suspension culture of cells in 3D allows the cells to grow in an environment that more closely mimics the physiological in vivo environment of the cells the transition from 2D to 3D culture needs to be properly performed and differentiation data obtained from 2D experiments need to be validated in 3D.
For this reason, EpiSCs-PPARy-CEBPa were adapted to 3D suspension cell growth and grown as aggregates; EpiSCs-PPARy-CEBPa expanded in an adherent 6-well cell plate were single celled with Accumax (00-4666-56, ThermoFisher Scientific) according to the manufacturer’s instructions and transferred to a 150 mL shaker flask in 12,5mL media and a RHO/ROCK pathway inhibitor and thereafter expanded for at least 3 cycles. Media during expansion in 3D was refreshed daily. 3D adapted EpiSCs-PPARy-CEBPa were subsequently used in shaker and bioreactor experiments.
To explore adipogenesis performance in 3D, 3 million cells/mL were inoculated in a 250 mL shaker flask containing 25 mL of media and EpiSCs-PPARy-CEBPa were differentiated using differentiation protocol D in the presence of additional insulin and dexamethasone . Media was changed every second day. Cells were collected during differentiation at day 6, stained with Oil Red O and DAPI and visualized by fluorescent microcopy using the pancake methodology previously described (Figure 5) mRNA relative gene expression for porcine PPARy and CEBPa Opti-Ox- derived mRNA and porcine endogenous PPARy, CEBPa, adiponectin, LPL, Perilipin-1 , FABP4, CD36 and CEBPp was analyzed as previously described herein. The relative gene expression did not differ significantly from the relative gene expression observed in cells grown in 2D culture (data not shown) confirming that the adipocytes were suitably adapted to growth and differentiation in 3D culture.
Example 7: EpiSCs-PPARy-CEBPa 3D differentiation in suspension-. Protocol optimization: Differentiation using protocol D and protocol F with KSR+lnsulin+Dexamethasone, with KSR+Dexamethasone (no extra insulin) and with KSR+ Insulin (No Dexamethasone).
To confirm that in 3D also additional insulin and dexamethasone can be left out, EpiSCs-PPARy- CEBPa were differentiated in shakers and the setup of example 5 was repeated in 3D. pEpiSC PPARy-CEBPa differentiated both, under the protocol D (mesodermal step+maturation step) and the protocol F (only maturation step) in 3D in suspension as well (Figure 8). I ntracellular triglycerides were also detectable in the center of the aggregate which points to a sufficient nutrient and factor perfusion inside of the 3D structure (including size aggregate). Thus pEpiSC PPARy-CEBPa are also capable of differentiation into adipocytes with no additional insulin and with no dexamethasone added in the maturation media, again confirming this model is more promising in terms costreduction (process and media) and because several small molecules can be left out for regulatory acceptance of cultivated meat.
Example 8: EpiSCs-PPARy-CEBPa 3D differentiation in suspension in bioreactor:
To explore if pEpiSC PPARy-CEBPa can be grown and differentiated in a bioreactor, a fed batch procedure was designed using an Ambr250 modular bioreactor system (Sartorius), where 6x106/mL undifferentiated cells were inoculated in 120mL DMEMF/12 medium (21041-025, Gibco) supplemented with KSR, BMP4, FGF2, Activin A, Glutamax and Ascorbic acid in the same concentrations described for previous experiments. Glucose concentration was maintained above 7 mM, temperature was kept at physiological levels, agitation speed was sufficient to assure aggregate size do not exceed the limits for nutrient perfusion, 7,5% Sodium bicarbonate was added on demand to maintain pH at 7,4 ± 0,5 and dissolved oxygen set-point was established between 30-70%. Additional insulin and doxycycline were added on days 0, 2, 4 and 6 while dexamethasone was only added once on day 2. Aggregates were collected on day 0, 3, 5 and 7 of differentiation for further analysis. Media components concentrations were monitored every 24 hours to identify
possible limitations (data not shown). Samples for neutral lipid quantification and gene expression analysis were obtained on days 0, 3, 5 and 7. Aggregate’s size were measured on day 0 and 6.
Intracellular triglycerides were already detected after 3 days of differentiation in pEpiSC PPARy- CEBPa, while lipid accumulation was constantly increasing until the end of the experiment at day 7 of differentiation (Figure 9). These results confirm that that pEpiSC PPARy-CEBPa can differentiate into adipocytes in a bioreactor, which highlight the potential of this model to be used in scaling-up processes.
Example 9: EpiSCs-PPARy-CEBPa differentiation in the absence of insulin
PPARy-CEBPa pEplSCs were seeded at 125000 cells/cm2 in 6-well plates pre-coated with Geltrex, in proliferation media + Fasudil at 3.5pM. Cells were homogeneously distributed in the wells and incubated overnight at 38.5 degrees, 5% CO2 to ensure their attachment. Adipocyte differentiation was induced the next day by refreshing the media with maturation media (Protocol F) supplemented with 0.5 pg/mL doxycycline and containing 20 pg/mL insulin (control, condition Figure 10A), 10 pg/mL insulin (condition Figure 10B), 5 pg/mL insulin (condition Figure 10C) or in the absence of insulin (condition Figure 10D). Free-insulin maturation media was also supplemented with 0.05 pg/mL IGF-1 (Condition Figure 10E) and 0.05 pg/mL IGF-1/LR3 (condition Figure 10F). Maturation media was replaced every two days and cells were incubated at 38.5 degrees, 5% CO2 during differentiation. Bright-field images were taken on day 8 of differentiation. These results confirm that insulin is not required for efficient differentiation.
Statements (features) and embodiments of the methods and compositions as disclosed herein are set out below. Each of the statements and embodiments as disclosed by the invention so defined may be combined with any other statement and/or embodiment unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
Embodiments
The present invention provides at least the following numbered statements/embodiments:
1 . A pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR- y protein, wherein the coding sequence for the PPAR- y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter;
wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
2. A pluripotent stem cell according to embodiment 1 , wherein the expression constructs of ii) and iii) are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site.
3. The pluripotent stem cell according to embodiment 1 or 2, wherein the cell is selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, embryonic cell lines, and somatic cell lines.
4. The pluripotent stem cell according to any one of embodiments 1 -3, wherein the pluripotent stem cells are of a livestock or poultry species.
5. The pluripotent stem cell according to embodiment 4, wherein the livestock species is porcine or bovine, preferably porcine.
6. The pluripotent stem cell according to any one of embodiments 2-5, wherein the expression construct that is inserted into the second genetic safe harbour site encodes a PPAR- y protein a linker and a CEBPa protein, preferably wherein the linker is P2A, more preferably wherein the linker comprises the sequence of SEQ ID NO: 3.
7. The pluripotent stem cell according to embodiment 6, wherein the construct comprises the sequence of SEQ ID NO: 4.
8. The pluripotent stem cell according to any one of embodiments 1-7, wherein the activity of the transcriptional regulator protein is controlled by an exogenously supplied substance derivative.
9. The pluripotent stem cell according to any one of embodiments 1-8, wherein the transcriptional regulator protein is selected from the group consisting of: tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor and an activation domain from the human NF-kB, preferably the transcriptional regulator protein is rtTA.
10. The pluripotent stem cell according to any one of embodiments 1-9, wherein the inducible promoter includes a Tet Responsive Element (TRE).
11. The pluripotent stem cell according to any one of embodiments 1-10, wherein the inducible promotor is a tetON promotor.
12. The pluripotent stem cell according to any one of embodiments 1-11 , wherein said first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene, preferably wherein the genetic safe harbour site are hROSA26 locus and the AAVS1 locus.
13. A method for the production of adipocytes, preferably white adipocytes, comprising a ) culturing the pluripotent stem cell according to any one of the preceding claims in a proliferation medium: followed by b) inducing adipocyte differentiation by adding the exogenous substance according to claim 8, preferably the proliferation and/or differentiation medium does not comprise insulin and/or dexamethasone.
14. The method according to embodiment 13, wherein the differentiation phase is at most 10 days, at most 9 days, 8 days, 7 days, 6 days, 5 days, 4 days or 3 days.
15. The method according to embodiment 13 or 14 wherein the produced adipocytes are for human and non-human dietary consumption.
16. Use of a pluripotent stem cell according to any one of embodiments 1-12 or use of the method for producing a adipocyte according to any one of embodiments 13-15 for tissue engineering, optionally for the production of cultured meat.
17. A food product comprising the pluripotent stem cell according to any one of embodiments 1-12 or the adipocytes obtained by the method according to any one of claims 13-15.
18. The food product according to embodiment 17, wherein the food product is cultured meat.
Claims
1 . A pluripotent stem cell comprising: i) an expression construct for expression of a transcriptional regulator protein inserted into a first genetic safe harbour site; ii) an expression construct for expression of a PPAR-y protein, wherein the coding sequence for the PPAR-y protein is operably linked to an inducible promoter; and, iii) an expression construct for expression of a CEBPa protein, wherein the coding sequence for the CEBPa protein is operably linked to an inducible promoter; wherein the expression constructs of ii) and iii) are inserted into at least one further genetic safe harbour site that is not the first genetic safe harbour site, and wherein the inducible promotor is regulated by the transcriptional regulator protein.
2. A pluripotent stem cell according to claim 1 , wherein the expression constructs of ii) and iii) are both inserted into a second genetic safe harbour site that is different from the first genetic safe harbour site.
3. The pluripotent stem cell according to claim 1 or 2, wherein the cell is selected from the group consisting of induced pluripotent stem cells, and embryonic cell lines.
4. The pluripotent stem cell according to any one of claims 1 -3, wherein the pluripotent stem cells are of a livestock or poultry species.
5. The pluripotent stem cell according to claim 4, wherein the livestock species is porcine or bovine, preferably porcine.
6. The pluripotent stem cell according to any one of claims 2-5, wherein the expression construct that is inserted into the second genetic safe harbour site encodes a PPAR-y protein a linker and a CEBPa protein, preferably wherein the linker is P2A, more preferably wherein the linker comprises the sequence of SEQ ID NO: 3.
7. The pluripotent stem cell according to claim 6, wherein the construct comprises the sequence of SEQ ID NO: 4.
8. The pluripotent stem cell according to any one of the preceding claims, wherein the activity of the transcriptional regulator protein is controlled by an exogenously supplied substance derivative.
9. The pluripotent stem cell according to any one of the preceding claims, wherein the transcriptional regulator protein is selected from the group consisting of: tetracycline responsive transcriptional activator protein (rtTa), Tetracycline repressor (TetR), VgEcR synthetic receptor or a hybrid
transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor and an activation domain from the human NF-kB, preferably the transcriptional regulator protein is rtTA.
10. The pluripotent stem cell according to any one of the preceding claims, wherein the inducible promoter includes a Tet Responsive Element (TRE).
11 . The pluripotent stem cell according to any one of the preceding claims, wherein the inducible promotor is a tetON promotor.
12. The pluripotent stem cell according to any one of the preceding claims, wherein said first and further genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene, preferably wherein the genetic safe harbour site are hROSA26 locus and the AAVS1 locus.
13. A method for the production of adipocytes, preferably white adipocytes, comprising a ) culturing the pluripotent stem cell according to any one of the preceding claims in a proliferation medium: followed by b) inducing adipocyte differentiation by adding the exogenous substance according to claim 8, preferably the proliferation and/or differentiation medium does not comprise insulin and/or dexamethasone.
14. The method according to claim 13, wherein the differentiation phase is at most 10 days, at most 9 days, 8 days, 7 days, 6 days, 5 days, 4 days or 3 days.
15. The method according to claims 13 or 14 wherein the produced adipocytes are for human and non-human dietary consumption.
16. Use of a pluripotent stem cell according to any one of claims 1-12 or use of the method for producing a adipocyte according to any one of claims 13-15 fortissue engineering, optionally for the production of cultured meat.
17. A food product comprising the pluripotent stem cell according to any one of claims 1 -12 or the adipocytes obtained by the method according to any one of claims 13-15.
18. The food product according to claim 17, wherein the food product is cultured meat.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22203081 | 2022-10-21 | ||
EP22203081.9 | 2022-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024084082A1 true WO2024084082A1 (en) | 2024-04-25 |
Family
ID=83994877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/079366 WO2024084082A1 (en) | 2022-10-21 | 2023-10-20 | Adipocyte maturation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024084082A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009378A1 (en) | 1994-09-19 | 1996-03-28 | The General Hospital Corporation | Overexpression of mammalian and viral proteins |
WO2010037130A2 (en) * | 2008-09-29 | 2010-04-01 | The General Hospital Corporation | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
US20120219530A1 (en) | 1999-04-15 | 2012-08-30 | The General Hospital Corporation | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
WO2013082106A1 (en) * | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
-
2023
- 2023-10-20 WO PCT/EP2023/079366 patent/WO2024084082A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009378A1 (en) | 1994-09-19 | 1996-03-28 | The General Hospital Corporation | Overexpression of mammalian and viral proteins |
US20120219530A1 (en) | 1999-04-15 | 2012-08-30 | The General Hospital Corporation | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
WO2010037130A2 (en) * | 2008-09-29 | 2010-04-01 | The General Hospital Corporation | Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore |
WO2013082106A1 (en) * | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
Non-Patent Citations (10)
Title |
---|
GOEKE ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 416, no. 1, 2012, pages 33 - 45 |
HUNSICKER ET AL., CHEMISTRY & BIOLOGY, vol. 16, no. 2, 2009, pages 173 - 180 |
KLOTZSCHE ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 26, 2005, pages 24591 - 24599 |
PAPAPETROU ET AL., NATURE BIOTECHNOLOGY, vol. 29, no. 1, 2011, pages 73 - 8 |
SCHLICHT ET AL., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 72, no. 8, 2006, pages 5637 - 5642 |
SHRESTHA DEWAN ET AL: "Genomics and epigenetics guided identifcation of tissue-specifc genomic safe harbors", GENOME BIOLOGY, 21 September 2022 (2022-09-21), XP093062654, Retrieved from the Internet <URL:https://www.researchgate.net/publication/363735490_Genomics_and_epigenetics_guided_identification_of_tissue-specific_genomic_safe_harbors> [retrieved on 20230711] * |
TIM AHFELDT ET AL: "Programming human pluripotent stem cells into white and brown adipocytes", NATURE CELL BIOLOGY, vol. 14, no. 2, 15 January 2012 (2012-01-15), London, pages 209 - 219, XP055559477, ISSN: 1465-7392, DOI: 10.1038/ncb2411 * |
TONTONOZ ET AL., CELL, vol. 79, 30 December 1994 (1994-12-30), pages 1147 - 1156 |
YUEN JR JOHN S K ET AL: "Perspectives on scaling production of adipose tissue for food applications", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 280, 29 November 2021 (2021-11-29), XP086908584, ISSN: 0142-9612, [retrieved on 20211129], DOI: 10.1016/J.BIOMATERIALS.2021.121273 * |
ZHANGSHU ET AL.: "DNA polymorphisms in bovine fatty acid synthase are associated with beef fatty acid composition 1", ANIMAL GENETICS, vol. 39, no. 1, 2008, pages 62 - 70, XP071535788, DOI: 10.1111/j.1365-2052.2007.01681.x |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11708587B2 (en) | Compositions and methods for increasing the efficiency of cell cultures used for food production | |
US20220183317A1 (en) | Hybrid meat substitute food products | |
US20200140821A1 (en) | Ex vivo meat production | |
US20230151330A1 (en) | Systems and methods for cell conversion | |
Zidarič et al. | Cultured meat: meat industry hand in hand with biomedical production methods | |
US20220298480A1 (en) | Methods for improving cell growth with species-specific or genus-specific proteins and the applications thereof | |
KR20220016846A (en) | Pluripotent cell aggregates and uses thereof | |
JP2021040578A (en) | Method for inducing immature oocytes and method for producing mature oocytes | |
Lee et al. | Unlocking the potential of stem cells: Their crucial role in the production of cultivated meat | |
WO2024084082A1 (en) | Adipocyte maturation | |
CN108472318A (en) | Humanization cardiac muscle | |
Kulus et al. | Bioreactors, scaffolds and microcarriers and in vitro meat production—current obstacles and potential solutions | |
US11991994B2 (en) | Method for producing recombinant proteins in insects | |
EP4367219A1 (en) | Foodstuffs comprising cells differentiated from engineered oligopotent stem cells | |
Yoneda et al. | Involvement of mouse and porcine PLCζ-induced calcium oscillations in preimplantation development of mouse embryos | |
WO2023150503A2 (en) | Gene-editing methods for embryonic stem cells | |
JP2024073421A (en) | Ex vivo meat production | |
CN117999343A (en) | Food product comprising cells differentiated from engineered oligopotent stem cells | |
IL307711A (en) | Generation of cell-based products for human consumption | |
Shah et al. | Biotechnological potential of stem cells in food-producing animals: A review | |
JP2023039157A (en) | Methods for producing recombinant cells, culture methods, recombinant cells, methods for producing expression vectors, and expression vectors | |
WO2019075557A1 (en) | Enhanced transfection efficiency of human pluripotent stem cells through the effects of retinoic acid analogue (ttnpb), rho-associated kinase inhibitor (y-27632), and ppar y agonist (pioglitazone) |